WO2023287212A1 - 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체 - Google Patents
조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체 Download PDFInfo
- Publication number
- WO2023287212A1 WO2023287212A1 PCT/KR2022/010262 KR2022010262W WO2023287212A1 WO 2023287212 A1 WO2023287212 A1 WO 2023287212A1 KR 2022010262 W KR2022010262 W KR 2022010262W WO 2023287212 A1 WO2023287212 A1 WO 2023287212A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disease
- antibody
- seq
- present
- amino acid
- Prior art date
Links
- 230000027455 binding Effects 0.000 title claims abstract description 140
- 210000003289 regulatory T cell Anatomy 0.000 title abstract description 53
- 101710160107 Outer membrane protein A Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 claims abstract description 90
- 108091007433 antigens Proteins 0.000 claims abstract description 86
- 102000036639 antigens Human genes 0.000 claims abstract description 86
- 239000012634 fragment Substances 0.000 claims abstract description 63
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 18
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 18
- 102000016844 Immunoglobulin-like domains Human genes 0.000 claims abstract description 15
- 108050006430 Immunoglobulin-like domains Proteins 0.000 claims abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 139
- 102000004169 proteins and genes Human genes 0.000 claims description 133
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 95
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 65
- 201000010099 disease Diseases 0.000 claims description 53
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 53
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 53
- 229920001184 polypeptide Polymers 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 41
- 239000000611 antibody drug conjugate Substances 0.000 claims description 28
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 26
- 208000023275 Autoimmune disease Diseases 0.000 claims description 19
- 201000006417 multiple sclerosis Diseases 0.000 claims description 19
- 230000004770 neurodegeneration Effects 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- 239000013604 expression vector Substances 0.000 claims description 17
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 17
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 230000009870 specific binding Effects 0.000 claims description 14
- 208000012902 Nervous system disease Diseases 0.000 claims description 13
- 230000011664 signaling Effects 0.000 claims description 13
- 206010012289 Dementia Diseases 0.000 claims description 12
- 208000006673 asthma Diseases 0.000 claims description 12
- 238000012216 screening Methods 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 9
- 210000004556 brain Anatomy 0.000 claims description 9
- 230000002757 inflammatory effect Effects 0.000 claims description 9
- 108060003951 Immunoglobulin Proteins 0.000 claims description 8
- 208000037976 chronic inflammation Diseases 0.000 claims description 8
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 8
- 102000018358 immunoglobulin Human genes 0.000 claims description 8
- 208000030090 Acute Disease Diseases 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- 206010003645 Atopy Diseases 0.000 claims description 7
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 7
- 206010052779 Transplant rejections Diseases 0.000 claims description 7
- 230000001154 acute effect Effects 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 7
- 102000014461 Ataxins Human genes 0.000 claims description 6
- 108010078286 Ataxins Proteins 0.000 claims description 6
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 6
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 6
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 6
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 6
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 6
- 208000023105 Huntington disease Diseases 0.000 claims description 6
- 206010065390 Inflammatory pain Diseases 0.000 claims description 6
- 208000014060 Niemann-Pick disease Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 208000024777 Prion disease Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 208000034799 Tauopathies Diseases 0.000 claims description 6
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 6
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 6
- 108020001507 fusion proteins Proteins 0.000 claims description 6
- 102000037865 fusion proteins Human genes 0.000 claims description 6
- 208000024908 graft versus host disease Diseases 0.000 claims description 6
- 201000010901 lateral sclerosis Diseases 0.000 claims description 6
- 208000005264 motor neuron disease Diseases 0.000 claims description 6
- 208000004296 neuralgia Diseases 0.000 claims description 6
- 208000021722 neuropathic pain Diseases 0.000 claims description 6
- 208000012111 paraneoplastic syndrome Diseases 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 6
- 208000020431 spinal cord injury Diseases 0.000 claims description 6
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
- 208000001640 Fibromyalgia Diseases 0.000 claims description 5
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 5
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 5
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 5
- 206010043781 Thyroiditis chronic Diseases 0.000 claims description 5
- 208000004631 alopecia areata Diseases 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 5
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 5
- 208000005987 polymyositis Diseases 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 5
- 208000023345 Autoimmune Diseases of the Nervous System Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 127
- 210000004027 cell Anatomy 0.000 description 69
- 235000001014 amino acid Nutrition 0.000 description 53
- 229940024606 amino acid Drugs 0.000 description 46
- 150000001413 amino acids Chemical class 0.000 description 44
- 238000002360 preparation method Methods 0.000 description 31
- 241000699666 Mus <mouse, genus> Species 0.000 description 30
- 238000012360 testing method Methods 0.000 description 30
- 230000014509 gene expression Effects 0.000 description 26
- 239000013598 vector Substances 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 20
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 20
- 210000001744 T-lymphocyte Anatomy 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 20
- 238000002372 labelling Methods 0.000 description 20
- 108090000317 Chymotrypsin Proteins 0.000 description 16
- 229960002376 chymotrypsin Drugs 0.000 description 16
- 235000005772 leucine Nutrition 0.000 description 16
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 15
- 108090000631 Trypsin Proteins 0.000 description 15
- 102000004142 Trypsin Human genes 0.000 description 15
- 238000006467 substitution reaction Methods 0.000 description 15
- 239000012588 trypsin Substances 0.000 description 15
- 239000000203 mixture Substances 0.000 description 13
- 238000012790 confirmation Methods 0.000 description 12
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 11
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 102000035195 Peptidases Human genes 0.000 description 11
- 108091005804 Peptidases Proteins 0.000 description 11
- 239000004365 Protease Substances 0.000 description 11
- 238000004132 cross linking Methods 0.000 description 11
- 206010033799 Paralysis Diseases 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- -1 aromatic amino acids Chemical class 0.000 description 9
- 238000012217 deletion Methods 0.000 description 9
- 230000037430 deletion Effects 0.000 description 9
- 238000003780 insertion Methods 0.000 description 9
- 230000037431 insertion Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 235000019419 proteases Nutrition 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- 238000002869 basic local alignment search tool Methods 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 210000002602 induced regulatory T cell Anatomy 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 6
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 6
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 210000003194 forelimb Anatomy 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 210000003141 lower extremity Anatomy 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 5
- 206010003694 Atrophy Diseases 0.000 description 5
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 5
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000009824 affinity maturation Effects 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 230000037444 atrophy Effects 0.000 description 5
- 201000009385 autoimmune disease of the nervous system Diseases 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 210000002443 helper t lymphocyte Anatomy 0.000 description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
- 238000004811 liquid chromatography Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 4
- 208000016192 Demyelinating disease Diseases 0.000 description 4
- 206010012305 Demyelination Diseases 0.000 description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 210000001364 upper extremity Anatomy 0.000 description 4
- 239000008096 xylene Substances 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- LHYQAEFVHIZFLR-UHFFFAOYSA-L 4-(4-diazonio-3-methoxyphenyl)-2-methoxybenzenediazonium;dichloride Chemical compound [Cl-].[Cl-].C1=C([N+]#N)C(OC)=CC(C=2C=C(OC)C([N+]#N)=CC=2)=C1 LHYQAEFVHIZFLR-UHFFFAOYSA-L 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 239000004971 Cross linker Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108091092584 GDNA Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 3
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010083674 Myelin Proteins Proteins 0.000 description 3
- 102000006386 Myelin Proteins Human genes 0.000 description 3
- 102100023302 Myelin-oligodendrocyte glycoprotein Human genes 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 101150099493 STAT3 gene Proteins 0.000 description 3
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 210000003162 effector t lymphocyte Anatomy 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000013401 experimental design Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 229940127121 immunoconjugate Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000004068 intracellular signaling Effects 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 210000004901 leucine-rich repeat Anatomy 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000005012 myelin Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 2
- 238000011818 5xFAD mouse Methods 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 102100037904 CD9 antigen Human genes 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010072051 Glatiramer Acetate Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 2
- 101000619640 Homo sapiens Leucine-rich repeats and immunoglobulin-like domains protein 1 Proteins 0.000 description 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 description 2
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 2
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108050003558 Interleukin-17 Proteins 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
- 102100022170 Leucine-rich repeats and immunoglobulin-like domains protein 1 Human genes 0.000 description 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 2
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 102100036840 T-box transcription factor TBX21 Human genes 0.000 description 2
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 2
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 210000000068 Th17 cell Anatomy 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 2
- 206010045555 Unresponsive to stimuli Diseases 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000006229 amino acid addition Effects 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- XJMXIWNOKIEIMX-UHFFFAOYSA-N bromo chloro 1h-indol-2-yl phosphate Chemical compound C1=CC=C2NC(OP(=O)(OBr)OCl)=CC2=C1 XJMXIWNOKIEIMX-UHFFFAOYSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 150000002540 isothiocyanates Chemical class 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000002501 natural regulatory T cell Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000944 nerve tissue Anatomy 0.000 description 2
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- UCLKLGIYGBLTSM-UHFFFAOYSA-N 1,2,3,4-tetrachloro-5-(2,5-dichlorophenyl)benzene Chemical compound ClC1=CC=C(Cl)C(C=2C(=C(Cl)C(Cl)=C(Cl)C=2)Cl)=C1 UCLKLGIYGBLTSM-UHFFFAOYSA-N 0.000 description 1
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- HWTAKVLMACWHLD-UHFFFAOYSA-N 2-(9h-carbazol-1-yl)ethanamine Chemical compound C12=CC=CC=C2NC2=C1C=CC=C2CCN HWTAKVLMACWHLD-UHFFFAOYSA-N 0.000 description 1
- WONRDHPFOHAWOG-UHFFFAOYSA-N 2-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=C(Cl)C=CC2=C1 WONRDHPFOHAWOG-UHFFFAOYSA-N 0.000 description 1
- BUOYTFVLNZIELF-UHFFFAOYSA-N 2-phenyl-1h-indole-4,6-dicarboximidamide Chemical compound N1C2=CC(C(=N)N)=CC(C(N)=N)=C2C=C1C1=CC=CC=C1 BUOYTFVLNZIELF-UHFFFAOYSA-N 0.000 description 1
- ACNUVXZPCIABEX-UHFFFAOYSA-N 3',6'-diaminospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(N)C=C1OC1=CC(N)=CC=C21 ACNUVXZPCIABEX-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- IITIZHOBOIBGBW-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole Chemical compound C1=CC=C2N(CC)CSC2=C1 IITIZHOBOIBGBW-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- COCMHKNAGZHBDZ-UHFFFAOYSA-N 4-carboxy-3-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]benzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(C([O-])=O)=CC=C1C(O)=O COCMHKNAGZHBDZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 102100030374 Actin, cytoplasmic 2 Human genes 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 101001073212 Arabidopsis thaliana Peroxidase 33 Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000773237 Homo sapiens Actin, cytoplasmic 2 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101100455496 Homo sapiens LRIG1 gene Proteins 0.000 description 1
- 101001038321 Homo sapiens Leucine-rich repeat protein 1 Proteins 0.000 description 1
- 101000619642 Homo sapiens Leucine-rich repeats and immunoglobulin-like domains protein 2 Proteins 0.000 description 1
- 101001017855 Homo sapiens Leucine-rich repeats and immunoglobulin-like domains protein 3 Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 101001123325 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-beta Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100022341 Integrin alpha-E Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- 101150032178 LRIG1 gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101150030213 Lag3 gene Proteins 0.000 description 1
- 102100040249 Leucine-rich repeat protein 1 Human genes 0.000 description 1
- 102100022173 Leucine-rich repeats and immunoglobulin-like domains protein 2 Human genes 0.000 description 1
- 102100033284 Leucine-rich repeats and immunoglobulin-like domains protein 3 Human genes 0.000 description 1
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- LUWJPTVQOMUZLW-UHFFFAOYSA-N Luxol fast blue MBS Chemical compound [Cu++].Cc1ccccc1N\C(N)=N\c1ccccc1C.Cc1ccccc1N\C(N)=N\c1ccccc1C.OS(=O)(=O)c1cccc2c3nc(nc4nc([n-]c5[n-]c(nc6nc(n3)c3ccccc63)c3c(cccc53)S(O)(=O)=O)c3ccccc43)c12 LUWJPTVQOMUZLW-UHFFFAOYSA-N 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101100120552 Mus musculus Foxp3 gene Proteins 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102100028961 Peroxisome proliferator-activated receptor gamma coactivator 1-beta Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000001183 RAG-1 Human genes 0.000 description 1
- 108060006897 RAG1 Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IYXMNTLBLQNMLM-UHFFFAOYSA-N benzene-1,4-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=C(N)C=C1 IYXMNTLBLQNMLM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- VYXSBFYARXAAKO-WTKGSRSZSA-N chembl402140 Chemical compound Cl.C1=2C=C(C)C(NCC)=CC=2OC2=C\C(=N/CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-WTKGSRSZSA-N 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 229940038717 copaxone Drugs 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000000375 direct analysis in real time Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- PYLIXCKOHOHGKQ-UHFFFAOYSA-L disodium;hydrogen phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O PYLIXCKOHOHGKQ-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012063 dual-affinity re-targeting Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003776 glatiramer acetate Drugs 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002614 leucines Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- COCAUCFPFHUGAA-MGNBDDOMSA-N n-[3-[(1s,7s)-5-amino-4-thia-6-azabicyclo[5.1.0]oct-5-en-7-yl]-4-fluorophenyl]-5-chloropyridine-2-carboxamide Chemical compound C=1C=C(F)C([C@@]23N=C(SCC[C@@H]2C3)N)=CC=1NC(=O)C1=CC=C(Cl)C=N1 COCAUCFPFHUGAA-MGNBDDOMSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- INCIMLINXXICKS-UHFFFAOYSA-M pyronin Y Chemical compound [Cl-].C1=CC(=[N+](C)C)C=C2OC3=CC(N(C)C)=CC=C3C=C21 INCIMLINXXICKS-UHFFFAOYSA-M 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000016515 regulation of signal transduction Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229940043267 rhodamine b Drugs 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- VBJGJHBYWREJQD-UHFFFAOYSA-M sodium;dihydrogen phosphate;dihydrate Chemical compound O.O.[Na+].OP(O)([O-])=O VBJGJHBYWREJQD-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 230000023944 tyrosine phosphorylation of Stat3 protein Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Definitions
- the present invention relates to an epitope of Lrig-1 (leucine-rich and immunoglobulin-like domains 1) protein, which is an antigen present on the surface of regulatory T cells, and an antibody or antigen-binding fragment specifically binding thereto.
- Lrig-1 leucine-rich and immunoglobulin-like domains 1
- the most important characteristic of any normal organism is the ability to recognize and eliminate non-self antigens while not reacting detrimentally to antigenic substances that make up the self. .
- Such unresponsiveness of the living body to self-antigens is referred to as immunologic unresponsiveness or tolerance.
- Self-tolerance occurs by eliminating lymphocytes that may have specific receptors for self-antigens, or by inactivating self-reactive functions after encountering self-antigens. When a problem arises in inducing or maintaining self-tolerance, an immune response against self-antigens occurs, and a disease caused by this is called an autoimmune disease.
- the regulatory T cells play an important role in naturally preventing the occurrence of excessive inflammation and immune response, but when autoimmune diseases and chronic inflammatory diseases occur, the function and number of regulatory T cells are significantly reduced. reported Therefore, in the case of patients with immune and inflammatory diseases, it is important that regulatory T cells are produced at normal levels, and this can be one of the treatments for these diseases.
- CDRs complementarity determining regions
- the CDR mainly serves to bind to the epitope of the antigen.
- the CDRs of each chain are typically referred to sequentially starting from the N-terminus as CDR1, CDR2, and CDR3, and are also identified by the chain in which the particular CDR is located.
- One object of the present invention is to provide an epitope of Lrig-1 (leucine-rich and immunoglobulin-like domains 1) protein present on the surface of regulatory T cells (Treg cells).
- Another object of the present invention is to provide an antibody or antigen-binding fragment capable of specifically binding to the epitope.
- Another object of the present invention is a nucleic acid molecule encoding the epitope of the present invention; an expression vector into which the nucleic acid molecule is inserted; and a host cell line transfected with the expression vector.
- Another object of the present invention is to provide a pharmaceutical composition for preventing or treating various diseases comprising an antibody or antigen-binding fragment capable of specifically binding to the epitope as an active ingredient.
- Another object of the present invention is to provide an antibody-drug conjugate (ADC) in which the antibody according to the present invention is combined with a drug for preventing or treating various diseases.
- ADC antibody-drug conjugate
- Another object of the present invention is to treat various diseases including antibody-drug conjugates as an active ingredient, for example, immune-related diseases;
- various diseases including antibody-drug conjugates as an active ingredient, for example, immune-related diseases;
- Another object of the present invention is an antibody or antigen-binding fragment capable of specifically binding to the epitope; and methods for preventing or treating various diseases using antibody-drug conjugates.
- the present invention relates to an epitope of Lrig-1 (leucine-rich and immunoglobulin-like domains 1) protein or an antibody or antigen-binding fragment that specifically binds to the epitope.
- Lrig-1 leucine-rich and immunoglobulin-like domains 1
- the "epitope” refers to a sequence of amino acids within an antigen in which amino acids (or a subset thereof) within the sequence are specifically recognized by an antibody or binding fragment, e.g., an antibody or binding fragment described herein. do.
- An epitope may include one or more antigenic determinants. For example, antibodies raised against an isolated peptide corresponding to a conformational epitope recognize some or all of that epitope sequence.
- the "Lrig-1 protein” is a transmembrane protein present on the surface of regulatory T cells, and includes an extracellular or lumenal leucine-rich repeat (LRR) and three immune-like domains. (immunoglobulin-like domains), transmembrane sequences, and cytoplasmic tails.
- the LRIG gene family includes LRIG1, LRIG2 and LRIG3, and the amino acids constituting each family are highly conserved.
- the LRIG1 gene is highly expressed in normal skin, and can regulate the proliferation of epithelial stem cells by expressing it in basal and hair follicle cells.
- the Lrig-1 protein may be a protein derived from mammals or mice, but is not limited thereto.
- the Lrig-1 protein may be Lrig-1 protein derived from mammals, such as humans, primates such as monkeys, and rodents such as mice and rats.
- the Lrig-1 protein may be human-derived Lrig-1 protein represented by SEQ ID NO: 1, which may be encoded by the nucleic acid sequence represented by SEQ ID NO: 2, but is not limited thereto.
- the Lrig-1 protein may be mouse-derived Lrig-1 protein represented by SEQ ID NO: 3, which may be encoded by the nucleic acid sequence represented by SEQ ID NO: 4, but is not limited thereto.
- the Lrig-1 protein may be an extracellular domain of the Lrig-1 protein, but is not limited thereto.
- the Lrig-1 extracellular domain of the present invention may be an extracellular domain of the Lrig-1 protein derived from mammals, such as humans, primates such as monkeys, and rodents such as mice and rats.
- the extracellular protein of the Lrig-1 protein may be an extracellular domain of the Lrig-1 protein derived from human or mouse, but is not limited thereto.
- the extracellular domain of the Lrig-1 protein may be represented by SEQ ID NO: 5 corresponding to the 35th to 794th amino acid sequence of the human-derived Lrig-1 protein, but is not limited thereto.
- the extracellular domain of the Lrig-1 protein may be represented by SEQ ID NO: 6 corresponding to the 35th to 794th amino acid sequence of the mouse-derived Lrig-1 protein, but is not limited thereto.
- an epitope of the Lrig-1 protein comprising at least one polypeptide selected from the group consisting of polypeptides consisting of the amino acid sequences represented by SEQ ID NOs: 35 to 45 is provided.
- the epitope of the Lirg-1 protein may be an epitope comprising at least one polypeptide selected from the group consisting of polypeptides consisting of the amino acid sequences represented by SEQ ID NOs: 35 to 40, but is not limited thereto not.
- the epitope of the Lrig-1 protein may be an epitope comprising at least one polypeptide selected from the group consisting of polypeptides consisting of the amino acid sequences represented by SEQ ID NO: 41 to SEQ ID NO: 45. It is not limited.
- the epitope of the Lrig-1 protein is located at positions 62 to 101, or 88 to 92, or 90 to 101, or 111 to 134, or 452 of the Lrig-1 protein. It may be a site corresponding to the 476th, or 472nd to 480th, or 542nd to 553rd base sequence.
- the epitope of the Lrig-1 protein may be a region corresponding to the 95th to 101st base sequence or the 472nd to 476th base sequence of the Lrig-1 protein.
- the epitope of the present invention may be a conformational epitope.
- the "conformational epitope” of the present invention is composed of a discontinuous amino acid sequence. These conformational epitopes react with the three-dimensional structure of the antibody antigen-binding site.
- nucleic acid molecule encoding the epitope provided in the present invention is provided.
- Nucleic acid molecules of the present invention include all nucleic acid molecules in which the amino acid sequence of a polypeptide provided in the present invention is translated into a polynucleotide sequence as known to those skilled in the art. Therefore, various polynucleotide sequences by ORF (open reading frame) can be prepared, and all of them are also included in the nucleic acid molecule of the present invention.
- ORF open reading frame
- an expression vector into which the isolated nucleic acid molecule provided in the present invention is inserted is provided.
- the "vector” is a nucleic acid molecule capable of transporting another nucleic acid to which a nucleic acid molecule is linked.
- a vector is a “plasmid,” which refers to a circular double-stranded DNA into which additional DNA segments can be ligated.
- a phage vector refers to a viral vector, in which additional DNA segments can be ligated into the viral genome.
- Certain vectors are capable of autonomous replication in the host cell into which they are introduced (e.g., bacterial vectors are episomal mammalian vectors having a bacterial origin of replication).
- vectors may integrate into the host cell's genome as it enters the host cell, thereby replicating along with the host genome.
- some vectors are capable of directing the expression of genes to which they are operatively linked.
- Such vectors are termed “recombinant expression vectors” or simply “expression vectors” herein.
- expression vectors useful in recombinant DNA techniques often exist in the form of plasmids.
- plasmid and vector may be used interchangeably because the plasmid is the most commonly used form among vectors.
- the expression vector in the present invention include commercially widely used pCDNA vectors, F, R1, RP1, Col, pBR322, ToL, and Ti vectors; cosmid; phages such as lambda, lambdoid, M13, Mu, p1 P22, Q ⁇ , T-even, T2, T3, and T7; It may be selected from the group consisting of plant viruses, but is not limited thereto, and all expression vectors known to those skilled in the art as expression vectors can be used in the present invention, and when selecting an expression vector, it depends on the properties of the host cell of interest.
- introducing a vector into a host cell it may be performed by calcium phosphate transfection, viral infection, DEAE-dextran controlled transfection, lipofectamine transfection or electroporation, but is not limited thereto.
- An introduction method suitable for the expression vector and host cell can be selected and used.
- the vector contains one or more selection markers, but is not limited thereto, and selection is possible depending on whether a product is produced using a vector that does not contain a selection marker. Selection of the selection marker is selected by the target host cell, and since this method is already known to those skilled in the art, the present invention is not limited thereto.
- a tag sequence may be inserted into the expression vector and fused thereto.
- the tag includes, but is not limited to, a hexa-histidine tag, a hemagglutinin tag, a myc tag, or a flag tag, and any tag that facilitates purification known to those skilled in the art can be used in the present invention.
- a host cell line transformed with the expression vector provided in the present invention is provided.
- the "host cell” includes an individual cell or cell culture that can be or has been a recipient of vector(s) for incorporation of a polypeptide insert.
- a host cell includes the progeny of a single host cell, which may not necessarily be completely identical (morphologically or in genomic DNA complement) to the original parent cell because of natural, accidental or deliberate mutations.
- Host cells include cells transformed in vivo with the polypeptide(s) of the present disclosure.
- the host cell may include cells of mammalian, plant, insect, fungal or cellular origin, for example, bacterial cells such as Escherichia coli, Streptomyces, and Salmonella typhimurium; fungal cells such as yeast cells and Pichia pastoris; Insect cells such as Drozophila and Spodoptera Sf9 cells; CHO (Chinese hamster ovary cells), SP2/0 (mouse myeloma), human lymphoblastoid, COS, NSO (mouse myeloma), 293T, Bow melanoma cells, HT-1080, BHK (Baby Hamster Kidney cells), HEK (Human Embryonic Kidney cells) or PERC.6 (Human retinal cells) animal cells; Or it may be a plant cell, but is not limited thereto, and any cell that can be used as a host cell line known to those skilled in the art can be used.
- bacterial cells such as Escherichia coli,
- the transformation method of the present invention is any method of injecting a desired vector into the host cell, and may include any known method capable of injecting the vector into the host cell, for example, a method using CaCl 2 , electroporation, microinjection, calcium phosphate precipitation, electroporation, liposome-mediated transfection, DEAE-dextran treatment, gene bombardment, and transformation using viruses, etc. may be used, but are limited thereto. It is not.
- a binding molecule specifically binding to the epitope of the present invention is provided.
- binding molecule of the present invention may be either an antibody or an antigen-binding fragment, but is not limited thereto.
- the "antibody” is a full-length antibody or a portion of an antibody that has the ability to bind to the Lrig-1 protein and competitively binds to the Lrig-1 antigenic determinant region with the binding molecule of the present invention. All inclusive.
- the "antibody” refers to a protein molecule that acts as a receptor that specifically recognizes an antigen, including an immunoglobulin molecule that is immunologically reactive with a specific antigen.
- the antigen may be Lrig-1 protein present on the surface of regulatory T cells. Preferably, it may specifically recognize the leucine rich region or immunoglobulin-like domain of the Lrig-1 protein, but is not limited thereto.
- the "immunoglobulin” has a heavy chain and a light chain, each of which includes a constant region and a variable region.
- the light chain and heavy chain variable regions include three variable regions called complementarity determining regions (hereinafter referred to as “CDRs”) and four framework regions.
- CDRs complementarity determining regions
- the CDR mainly serves to bind to the antigenic determinant (Epitope) of the antigen.
- the CDRs of each chain are typically referred to sequentially starting from the N-terminus as CDR1, CDR2, and CDR3, and are also identified by the chain in which the particular CDR is located.
- the antibody or antigen-binding fragment thereof provided herein comprises heavy chain CDRs and light chain CDRs selected from the CDRs provided herein, or includes conservative variants of the CDRs provided herein. It is a chimeric antibody or fragment that
- variants of an amino acid sequence include amino acid insertion variants, amino acid addition variants, amino acid deletion variants and/or amino acid substitution variants.
- Amino acid deletion variants comprising deletions at the N-terminus and/or C-terminus of a protein are also referred to as N-terminal and/or C-terminal truncation variants.
- Amino acid insertion variants include insertions of single or two or more amino acids in a particular amino acid sequence.
- amino acid sequence variants with insertions one or more amino acid residues are inserted at specific sites in the amino acid sequence, but random insertions with appropriate screening of the resulting product are also possible.
- Amino acid addition variants include amino-terminal and/or carboxy-terminal fusions of one or more amino acids, such as 1, 2, 3, 5, 10, 20, 30, 50, or more amino acids.
- Amino acid deletion variants are characterized by the removal of one or more amino acids from the sequence, such as the removal of 1, 2, 3, 5, 10, 20, 30, 50, or more amino acids. Deletions can be anywhere in the protein.
- Amino acid substitution variants are characterized in that at least one residue in the sequence is removed and another residue is inserted in its place. It is preferred that the modification is at a position in the amino acid sequence that is not conserved between homologous proteins or peptides and/or replaces an amino acid with another amino acid having similar properties.
- the amino acid changes in the protein variants are conservative amino acid changes, ie substitutions of similarly charged or uncharged amino acids. Conservative amino acid changes include substitution of one of the family of amino acids in which the side chain is related.
- Naturally occurring amino acids generally fall into four families: acidic (aspartate, glutamate), basic (lysine, arginine, histidine), and non-polar (alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan). , and uncharged polar (glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine) amino acids. Phenylalanine, tryptophan, and tyrosine are sometimes grouped together as aromatic amino acids.
- the degree of similarity, preferably identity, between a given amino acid sequence and an amino acid sequence that is a variant of the given amino acid sequence is at least about 60%, 65%, 70%, 80%, 81%, 82%, 83%, will be 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% .
- the degree of similarity or identity is preferably at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70% of the full length of the reference amino acid sequence, It is given for an amino acid region that is at least about 80%, at least about 90% or about 100%.
- the degree of similarity or identity is at least about 20, at least about 40, at least about 60, at least about 80, preferably contiguous amino acids. , at least about 100, at least about 120, at least about 140, at least about 160, at least about 180, or about 200 amino acids.
- the degree of similarity or identity is given over the full length of a reference amino acid sequence. Alignment to determine sequence similarity, preferably sequence identity, can be performed using tools known in the art, preferably best sequence alignment, for example using standard settings, preferably EMBOSS::needle, Matrix (Matrix). ): Align using Blosum62, Gap Open 10.0, Gap Extend 0.5.
- Sequence similarity refers to the percentage of amino acids that are identical or exhibit conservative amino acid substitutions.
- Sequence identity refers to the percentage of identical amino acids between the sequences.
- percent identity is intended to denote the percentage of identical amino acid residues between two sequences to be compared, obtained after best alignment, this percentage is purely statistical and the differences between the two sequences are randomly distributed and over their full length.
- Sequence comparison between two amino acid sequences is usually done by optimally aligning these sequences and then comparing them, the comparison being done segment by segment or by "comparison windows” to identify and compare local regions of sequence similarity.
- Optimal alignment of sequences for comparison may be performed, in addition to manually, by local homology algorithms or by similarity search methods, or by computer programs using these algorithms (Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA). Genetics Computer Group's Wisconsin Genetics Software Package (GAP, BESTFIT, FASTA, BLAST P, BLAST N and TFASTA) of the Wisconsin Genetics Software Package).
- Percent identity is calculated by determining the number of identical positions between the two sequences being compared, dividing this number by the number of positions compared, and multiplying the result obtained by 100 to obtain the percentage identity between these two sequences.
- Homologous amino acid sequences are according to the present invention at least 40%, in particular at least 50%, at least 60%, at least 70%, at least 80%, at least 90% and preferably at least 95%, at least 98 or at least 99% of the amino acid residues. indicates identity.
- Amino acid sequence variants described herein can be readily prepared by one skilled in the art, eg, by recombinant DNA manipulation. The manipulation of DNA sequences to produce proteins and peptides with substitutions, additions, insertions or deletions is well known.
- the peptides and amino acid variants described herein can be readily prepared with the aid of known peptide synthesis techniques, such as, for example, by solid phase synthesis and similar methods.
- an antibody or antigen-binding fragment thereof provided herein comprises a heavy chain CDR and a light chain CDR selected from the CDRs provided herein, or a humanized antibody comprising conservative variants of the CDRs provided herein, or it's a snippet
- an antibody or antigen-binding fragment thereof provided herein comprises a light chain and/or heavy chain comprising a sequence provided herein or conservative variants thereof.
- a conservative variant is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% homologous to a reference sequence provided herein. have a sequence
- conservative variants comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 10 or more amino acid substitutions, insertions or deletions. do.
- an antibody that specifically binds to the Lrig-1 protein provided herein comprises a sequence provided herein or a conservative variant thereof.
- conservative variants include conservative amino acid substitutions, insertions or deletions.
- conservative amino acid substitutions are substitutions of one amino acid with another amino acid having similar structural or chemical properties, eg, similar side chains, while retaining the biological activity of the reference sequence. Exemplary conservative substitutions are well known in the art.
- the "full-length antibody” has a structure having two full-length light chains and two full-length heavy chains, each light chain connected to the heavy chain by a disulfide bond, and IgA, IgD, IgE, IgM, and IgG.
- the IgG includes IgG1, IgG2, IgG3 and IgG4 as its subtype.
- the "antigen-binding fragment” refers to a fragment having an antigen-binding function
- examples of antigen-binding fragments include 1 light chain variable region (VL) and heavy chain variable region (VH) and light chain constants.
- the antigen-binding fragment may be a Fab or F(ab') 2 fragment using a proteolytic enzyme, for example, papain or pepsin, and may be prepared through genetic recombination technology.
- the antibodies and fragments thereof are monoclonal antibodies, polyclonal antibodies, chimeric antibodies, humanized antibodies, human antibodies, bivalent ( bivalent), bispecific molecule, minibody, domain antibody, bispecific antibody, antibody mimetic, unibody, diabody, triabody, tetrabody ( tetrabody) or a fragment thereof, but is not limited thereto.
- the "chimeric antibody” is an antibody in which the variable region of a mouse antibody and the constant region of a human antibody are recombined, and the immune response is greatly improved compared to the mouse antibody.
- the "humanized antibody” refers to an antibody in which the protein sequence of an antibody derived from a non-human species is modified to resemble an antibody variant naturally produced in a human.
- the humanized antibody may be prepared by recombination of a mouse-derived CDR with a human antibody-derived FR to prepare a humanized variable region, and then recombination with the constant region of a desired human antibody to prepare a humanized antibody.
- the binding molecule may be provided as a bispecific antibody or a bispecific antigen-binding fragment capable of binding to Lrig-1 protein and other proteins.
- the bispecific antibody and bispecific antigen-binding fragment may comprise a binding molecule according to the present invention.
- the bispecific antibodies and bispecific antigen-binding fragments include an antigen-binding domain capable of binding to Lrig-1 protein, wherein the antigen-binding domain capable of binding to Lrig-1 protein It may comprise or consist of a binding molecule according to the present invention.
- Bispecific antibodies and bispecific antigen-binding fragments provided by the present invention include an antigen-binding domain, which is a binding molecule capable of binding to the Lrig-1 protein according to the present invention, and an antigen-binding domain capable of binding to other target proteins.
- the antigen-binding domain capable of binding to another target protein is a protein other than Lrig-1 protein, but is not limited thereto, and may be, for example, an antigen-binding domain capable of binding to PD-1 or a cell surface receptor. However, it is not limited thereto.
- bispecific antibodies and bispecific antigen-binding fragments according to the present invention may be provided in any suitable format, such as those described in documents incorporated herein by reference in their entirety.
- a bispecific antibody or bispecific antigen-binding fragment may be a bispecific antibody conjugate (eg an IgG2, F(ab')2 or CovX-body), a bispecific IgG or IgG-like molecule (eg an IgG2, F(ab')2 or CovX-body).
- Db diabodies
- dsDb dsDb
- DART scDb
- tandAbs tandem scFv
- tandem dAb/VHH triple body
- Fab-scFv Fab-scFv
- F(ab')2-scFv2 bispecific Fc and CH3 fusion proteins
- taFv-Fc di-diabody, scDb-CH3, scFv-Fc-scFv, HCAb-VHH, scFv-kih-Fc, or scFv-kih-CH3), or a bispecific fusion protein such as scFv2-albumin , scDb-albumin, taFv-toxin, DNL-Fab3, DNL-Fab4-IgG, DNL-Fab4-IgG-cytokine 2).
- scFv2-albumin scDb-albumin
- taFv-toxin DNL-Fab3, DNL-Fab4-IgG, DNL-Fab4-IgG-cytokine 2
- the method for producing the bispecific antibody in the present invention includes chemical cross-linking of an antibody or antibody fragment with a reducing disulfide or non-reducing thioether bond.
- a reducing disulfide or non-reducing thioether bond For example, N-succinimidyl-3-(-2-pyridyldithio)-propionate (SPDP) is used to generate disulfide-linked bispecific F(ab)2 heterodimers, for example, It can be used to chemically cross-link Fab fragments via hinge region SH-groups.
- SPDP N-succinimidyl-3-(-2-pyridyldithio)-propionate
- another method for producing the bispecific antibody in the present invention is to fuse an antibody-producing hybridoma with, for example, polyethylene glycol to create a quadroma cell capable of secreting the bispecific antibody.
- Bispecific antibodies and bispecific antigen-binding fragments according to the present invention can be produced recombinantly, for example by expression from a nucleic acid construct encoding a polypeptide for the antigen-binding molecule.
- two antigen binding domains i.e., light and heavy chain variable domains for an antigen binding domain capable of binding PD-1, etc., and light and heavy chain variable domains for an antigen binding domain capable of binding other target proteins.
- a DNA construct comprising sequences encoding the light and heavy chain variable domains for ) and a suitable linker between the antigen binding domains or a dimerization domain can be prepared by molecular cloning techniques.
- Recombinant bispecific antibodies may then be produced by expression (eg in vitro) of the construct in a suitable host cell (eg mammalian host cell), and the expressed recombinant bispecific antibody may then optionally be purified.
- An antibody may be produced by an affinity maturation process that results in a modified antibody with improved affinity of the antibody for an antigen compared to the unmodified parental antibody.
- Affinity matured antibodies can be produced by procedures known in the art.
- the binding molecule provided in the present invention may include a variant of the amino acid sequence as long as it can specifically bind to the Lrig-1 protein.
- changes may be made to the amino acid sequence of an antibody to improve its binding affinity and/or other biological properties. Such modifications include, for example, deletions, insertions and/or substitutions of residues in the amino acid sequence of the antibody.
- amino acid variations are made based on the relative similarity of amino acid side chain substituents, such as hydrophobicity, hydrophilicity, charge, size, etc.
- Analysis of the size, shape and type of amino acid side chain substituents revealed that arginine, lysine and histidine are all positively charged residues; Alanine, glycine and serine have similar sizes; It can be seen that phenylalanine, tryptophan and tyrosine have similar shapes. Therefore, based on these considerations, arginine, lysine and histidine; alanine, glycine and serine; And phenylalanine, tryptophan and tyrosine can be said to be biologically functional equivalents.
- each amino acid is given a hydrophobicity index according to its hydrophobicity and charge: Isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cysteine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); Tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); Lysine (-3.9); and arginine (-4.5).
- the hydrophobic amino acid index is very important in conferring the interactive biological function of proteins. It is a known fact that amino acids having similar hydrophobicity indexes should be substituted to retain similar biological activities. When a mutation is introduced with reference to the hydrophobicity index, substitution is made between amino acids exhibiting a difference in hydrophobicity index, preferably within ⁇ 2, more preferably within ⁇ 1, and even more preferably within ⁇ 0.5.
- Amino acid exchanges in proteins that do not entirely alter the activity of the molecule are known in the art.
- the most commonly occurring exchanges are amino acid residues Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/ It is an exchange between Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, and Gln/Glu.
- the binding molecule of the present invention is construed to include sequences showing substantial identity with the sequences listed in the Sequence Listing.
- the term "substantial identity” refers to a sequence of at least 61% when the sequence of the present invention and any other sequence are paralleled so as to correspond as much as possible, and the paralleled sequence is analyzed using an algorithm commonly used in the art. It means a sequence exhibiting homology, more preferably 70% homology, even more preferably 80% homology, and most preferably 90% homology.
- Alignment methods for sequence comparison are known in the art. Various methods and algorithms for alignment can be accessed from NCBI Basic Local Alignment Search Tool (BLAST), NBCI (National Center for Biological Information), etc. available. BLAST is accessible at this address (www.ncbi.nlm.nih.gov/BLAST/). A sequence homology comparison method using this program can be checked online (www.ncbi.nlm.nih.gov/BLAST/blast_help.html).
- the binding molecule preferably the antibody
- the binding molecule may be produced by a conventional method for producing antibodies, but may also be produced by affinity maturation.
- the affinity maturation refers to a process in which activated B cells produce antibodies with increased affinity for an antigen during an immune response.
- the affinity maturation may generate antibodies or antibody fragments produced by affinity maturation based on the principle of mutation and selection, just like a process that occurs in nature.
- the "monoclonal antibody” refers to an antibody molecule of a single molecular composition obtained from substantially the same antibody population, and exhibits a single binding specificity and affinity for a specific epitope.
- the "binding" or “specific binding” refers to the affinity of the antibody or antibody composition for the antigen of the present application.
- “Specific binding” in antigen-antibody binding can typically be distinguished from non-specific background binding if the dissociation constant (Kd) is less than 1x10 -5 M or less than 1x10 -6 M or less than 1x10 -7 M.
- Specific binding can be detected by methods known in the art, such as ELISA, surface plasmon resonance (SPR), immunoprecipitation, coprecipitation, and the like, and non-specific binding and specific binding Include an appropriate control group that can be differentiated.
- the antibody or antigen-binding fragment of the present invention may exist as a multimer, such as a dimer, a trimer, a tetramer, or a pentamer, including at least a portion of the antigen-binding ability of a monomer.
- These multimers also include homomultimers or heteromultimers. Since antibody multimers contain multiple antigen-binding sites, they have superior antigen-binding ability compared to monomers. Multimers of antibodies are also easy to construct multifunctional (bifunctional, trifunctional, tetrafunctional) antibodies.
- multifunctional refers to an antibody or antigen-binding fragment having two or more activities or functions (eg, antigen-binding ability, enzyme activity, ligand or receptor binding ability).
- the antibody of the present invention Polypeptides having enzymatic activity, for example, luciferase, acetyltransferase, galactosidase and the like can be coupled.
- Multifunctional antibodies also include antibodies in the form of multivalent or multispecific (bispecific, trispecific, etc.).
- the antibody or antigen-binding fragment according to the present invention specifically binds to an epitope comprising a polypeptide represented by any one of the amino acid sequences of SEQ ID NOs: 35 to 45 present on regulatory T cells, thereby inhibiting the function of the regulatory T cells.
- various diseases such as immune-related diseases; Alternatively, neurodegenerative diseases or neuroinflammatory diseases can be prevented or treated.
- the “immune-related disease” of the present invention may be at least one selected from the group consisting of autoimmune disease, graft-versus-host disease, organ transplant rejection, asthma, atopy, and acute or chronic inflammatory disease, but is limited thereto It is not.
- the autoimmune disease of the present invention is rheumatoid arthritis, systemic scleroderma, systemic lupus erythematosus, atopic dermatitis, psoriasis, alopecia areata, asthma, Crohn's disease, Behçetsi disease, Sjögren's syndrome, Guilla-Barré syndrome, chronic thyroiditis, multiple sclerosis , polymyositis, ankylosing spondylitis, fibromyalgia, and polyarteritis nodosa, but may be at least one selected from the group consisting of, but is not limited thereto.
- “Cranial nervous system disease” for preventing, improving or treating the composition provided in the present invention may be a neurodegenerative disease or a neuroinflammatory disease.
- neurodegenerative disease and “neuroinflammatory disease” of the present invention include stroke, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, Niemann-Pick disease , prion disease, Creutzfeldt-Jakob disease, frontotemporal dementia, Lewy dementia, AlzAmyotrophic lateral sclerosis, Paraneoplastic syndrome, corticobasal degeneration, Select from the group consisting of systemic atrophy, progressive supranuclear palsy, autoimmune disease of the nervous system, spinocerebellar ataxia, inflammatory and neuropathic pain, cerebrovascular disease, spinal cord injury and tauopathy It may be, but is not limited thereto.
- a binding molecule, antibody or antigen-binding fragment provided by the present invention and an antibody-drug conjugate (Antibody-Drug Conjugate, ADC) comprising a drug is provided.
- ADC Antibody-Drug Conjugate
- the "antibody-drug conjugate (ADC)" refers to a form in which a drug and an antibody are chemically linked without reducing the biological activity of the antibody and the drug.
- the antibody-drug conjugate is a form in which a drug is bound to an amino acid residue at the N-terminus of the heavy and/or light chain of an antibody, specifically, a drug to an ⁇ -amine group at the N-terminus of the heavy and/or light chain of an antibody. refers to this combined form.
- the "drug” may mean any substance having a specific biological activity in cells, which is a concept including DNA, RNA, or peptide.
- the drug may be in a form containing a reactive group capable of reacting with an ⁇ -amine group and cross-linking, and also includes a form in which a linker including a reactive group capable of reacting with an ⁇ -amine group and cross-linking is connected.
- the type is not particularly limited. It includes all types that react with known amine groups. Examples include Isothiocyanate, Isocyanates, Acyl Azide, NHS ester, Sulfonyl chloride, Aldehyde, Glyoxal, Epoxide, Oxirane, Carbonate, Aryl halide, Imidoester, Carbodiimide, Anhydride and Fluorophenyl ester), but is not limited thereto.
- the antibody-drug conjugate is the antibody or antigen-binding fragment comprising the epitope of the present invention, that is, Lrig-1 protein; or an epitope comprising a polypeptide consisting of a partial amino acid sequence of an extracellular domain of Lrig-1 protein; or an antibody or antigen-binding fragment that specifically binds to an epitope comprising a polypeptide represented by any one of amino acid sequences of SEQ ID NOs: 7 to 17, wherein the drug is an antibody that specifically binds to Lrig-1 protein
- Any drug capable of treating a disease targeted by may be included, for example, a drug capable of treating an immune-related disease; Alternatively, it may be a drug capable of treating neurodegenerative diseases or neuroinflammatory diseases, but is not limited thereto.
- the antibody or antigen-binding fragment provided by the present invention or antibody-drug conjugates (Antibody-Drug Conjugate, ADC) as an active ingredient, including various diseases, for example, immune-related diseases; Or it provides a pharmaceutical composition for the prevention or treatment of brain nervous system disease.
- ADC Antibody-Drug Conjugate
- a binding molecule, antibody or antigen-binding fragment included as an active ingredient in the pharmaceutical composition in the present invention specifically binds to an epitope comprising a polypeptide represented by any one of the amino acid sequences of SEQ ID NOs: 35 to 45 to regulate the function of the regulatory T cells, and to effector T cells Through the process of regulating activity, various diseases can be treated very effectively.
- the “immune-related disease” of the present invention may be at least one selected from the group consisting of autoimmune disease, graft-versus-host disease, organ transplant rejection, asthma, atopy, and acute or chronic inflammatory disease, but is limited thereto It is not.
- the autoimmune disease of the present invention is rheumatoid arthritis, systemic scleroderma, systemic lupus erythematosus, atopic dermatitis, psoriasis, alopecia areata, asthma, Crohn's disease, Behçetsi disease, Sjögren's syndrome, Guilla-Barré syndrome, chronic thyroiditis, multiple sclerosis , polymyositis, ankylosing spondylitis, fibromyalgia, and polyarteritis nodosa, but may be at least one selected from the group consisting of, but is not limited thereto.
- “Cranial nervous system disease” for preventing, improving or treating the composition provided in the present invention may be a neurodegenerative disease or a neuroinflammatory disease.
- neurodegenerative disease and “neuroinflammatory disease” of the present invention include stroke, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, Niemann-Pick disease , prion disease, Creutzfeldt-Jakob disease, frontotemporal dementia, Lewy dementia, AlzAmyotrophic lateral sclerosis, Paraneoplastic syndrome, corticobasal degeneration, Select from the group consisting of systemic atrophy, progressive supranuclear palsy, autoimmune disease of the nervous system, spinocerebellar ataxia, inflammatory and neuropathic pain, cerebrovascular disease, spinal cord injury and tauopathy It may be, but is not limited thereto.
- an immune-related disease comprising, as an active ingredient, a Chimeric Antigen Receptor (CAR) comprising an antigen-specific binding domain, a linking domain, and a CD3 zeta ( ⁇ ) signaling domain, or Provided is a pharmaceutical composition for preventing or treating brain nervous system diseases.
- CAR Chimeric Antigen Receptor
- ⁇ CD3 zeta
- chimeric antigen receptor means an engineered receptor comprising an extracellular antigen binding domain and an intracellular signaling domain.
- CAR single chain variable fragment
- the binding domain may include a single chain variable fragment (scFv) capable of specifically recognizing the Lrig-1 protein.
- scFv single chain variable fragment
- the "single chain variable fragment” or “scFv” refers to a fusion protein of a variable heavy chain (VH) and a variable light chain (VL) of an antibody by a peptide linker between VL and VH.
- the VH domain and the VL domain may be connected through a flexible linker.
- the flexible linker is about 10 to 30 amino acids (eg, 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6 or 5 amino acids), preferably 15 amino acids long.
- the linker length can act as an important determining site for chimeric antigen receptors, so a linker shorter than the above range can increase affinity, but also cause intracellular multimer formation to impair CAR expression. On the other hand, linkers longer than this range may reduce antigen affinity by moving the VL and VH CDRs farther apart in space.
- the chimeric antigen receptor of the present invention may further include at least one of a hinge region (or spacer) and a signaling domain.
- the hinge region is a part connecting the antigen-binding domain and the transmembrane domain, and is also called a 'spacer', and has the purpose of extending the antigen-binding domain from the T cell membrane or the NK cell membrane.
- the hinge region can be obtained from any suitable sequence from any genus, including, for example, human or parts thereof, or CD8, CD28, 4-1BB, OX40 commonly used in the art.
- the hinge region may include one selected from immunoglobulins (eg, IgG1, IgG2, IgG3, IgG4, and IgD) without being limited to immunoglobulins, but is not limited thereto.
- immunoglobulins eg, IgG1, IgG2, IgG3, IgG4, and IgD
- the signaling domain refers to a part of a chimeric antigen receptor found or engineered to be found inside a T cell.
- the signaling domain may or may not include a transmembrane domain that serves to fix the chimeric antigen receptor in the plasma membrane of T cells.
- the transmembrane domain and the signaling domain may be derived from the same protein (eg, CD3 zeta ( ⁇ ) molecule), or the transmembrane domain and the signaling domain may be derived from different proteins (eg, CD3 zeta ( ⁇ ) molecule).
- CD3 zeta ( ⁇ ) molecule the transmembrane domain of CD28 and the intracellular signaling domain of the CD3 zeta ( ⁇ ) molecule, or vice versa).
- the transmembrane domain includes, for example, T cell receptor ⁇ or ⁇ chain, all or part of the CD3 zeta ( ⁇ ) chain, CD28, CD3 ⁇ , CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, ICOS, CD154, functional derivatives thereof, or combinations thereof, but is not limited thereto.
- the costimulatory domain comprises 4-1BB (CD137); OX40; CD27; CD28; CD30; CD40; PD-1; CD2; CD7; CD258; natural killer group 2 member C (NKG2C); natural killer group 2 member (NKG2D); B7-H3; CD83; ICAM-1; ligands that bind to LFA-1 (CD11a/CD18) or ICOS; active fragments thereof; functional derivatives thereof; or a functional signaling domain derived from a polypeptide comprising a combination thereof, but is not limited thereto.
- 4-1BB CD137
- OX40 CD27; CD28; CD30; CD40; PD-1; CD2; CD7; CD258; natural killer group 2 member C (NKG2C); natural killer group 2 member (NKG2D); B7-H3; CD83; ICAM-1; ligands that bind to LFA-1 (CD11a/CD18) or ICOS; active fragments thereof; functional derivatives thereof; or a
- the signaling domain is all or part of CD3 zeta ( ⁇ ), common FcR gamma (FcER1G), FcgammaRIIIa, FcRbeta (Fc epsilon lip), CD3gamma, CD3delta, CD3 epsilon, CD79a, CD79b,
- DAP10 DNAX-activating protein 10
- DAP12 DNAX-activating protein 12
- an active fragment thereof a functional derivative thereof, or a combination thereof
- the “immune-related disease” of the present invention may be at least one selected from the group consisting of autoimmune disease, graft-versus-host disease, organ transplant rejection, asthma, atopy, and acute or chronic inflammatory disease, but is limited thereto It is not.
- the autoimmune disease of the present invention is rheumatoid arthritis, systemic scleroderma, systemic lupus erythematosus, atopic dermatitis, psoriasis, alopecia areata, asthma, Crohn's disease, Behçetsi disease, Sjögren's syndrome, Guilla-Barré syndrome, chronic thyroiditis, multiple sclerosis , polymyositis, ankylosing spondylitis, fibromyalgia, and polyarteritis nodosa, but may be at least one selected from the group consisting of, but is not limited thereto.
- “Cranial nervous system disease” for preventing, improving or treating the composition provided in the present invention may be a neurodegenerative disease or a neuroinflammatory disease.
- neurodegenerative disease and “neuroinflammatory disease” of the present invention include stroke, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, Niemann-Pick disease , prion disease, Creutzfeldt-Jakob disease, frontotemporal dementia, Lewy dementia, AlzAmyotrophic lateral sclerosis, Paraneoplastic syndrome, corticobasal degeneration, Select from the group consisting of systemic atrophy, progressive supranuclear palsy, autoimmune disease of the nervous system, spinocerebellar ataxia, inflammatory and neuropathic pain, cerebrovascular disease, spinal cord injury and tauopathy It may be, but is not limited thereto.
- prevention may include without limitation any act of blocking or suppressing or delaying the symptoms of a disease by using the pharmaceutical composition of the present invention.
- treatment may include without limitation any action that improves or benefits the symptoms of a disease by using the pharmaceutical composition of the present invention.
- the pharmaceutical composition may be in the form of capsules, tablets, granules, injections, ointments, powders or beverages, and the pharmaceutical composition may be intended for humans.
- the pharmaceutical compositions are not limited thereto, but are formulated in the form of oral formulations such as powders, granules, capsules, tablets, aqueous suspensions, external preparations, suppositories and sterile injection solutions according to conventional methods, respectively.
- the pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier.
- Pharmaceutically acceptable carriers may include binders, lubricants, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, pigments, flavors, etc. for oral administration, and buffers, preservatives, and painless agents for injections.
- the dosage form of the pharmaceutical composition of the present invention may be variously prepared by mixing with a pharmaceutically acceptable carrier as described above.
- a pharmaceutically acceptable carrier for example, for oral administration, it can be prepared in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, etc., and in the case of injections, it can be prepared in unit dosage ampoules or multiple dosage forms. there is.
- it may be formulated into solutions, suspensions, tablets, capsules, sustained-release preparations, and the like.
- examples of carriers, excipients and diluents suitable for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose , methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil, and the like can be used.
- fillers, anti-agglomerating agents, lubricants, wetting agents, flavoring agents, emulsifiers, preservatives, and the like may be further included.
- the route of administration of the pharmaceutical composition in the present invention is not limited to these, but oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, This includes sublingual or rectal. Oral or parenteral administration is preferred.
- parenteral includes subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
- the pharmaceutical composition of the present invention may also be administered in the form of a suppository for rectal administration.
- the pharmaceutical composition of the present invention depends on various factors including the activity of the specific compound used, age, body weight, general health, sex, diet, administration time, route of administration, excretion rate, drug combination and severity of the specific disease to be prevented or treated. It can vary widely, and the dosage of the pharmaceutical composition varies depending on the patient's condition, body weight, degree of disease, drug type, administration route and period, but can be appropriately selected by those skilled in the art, and is 0.0001 to 50 mg/kg per day. Alternatively, it may be administered at 0.001 to 50 mg/kg. Administration may be administered once a day, or may be administered in several divided doses. The dosage is not intended to limit the scope of the present invention in any way.
- the pharmaceutical composition according to the present invention may be formulated into a pill, dragee, capsule, liquid, gel, syrup, slurry, or suspension.
- a binding molecule according to the present invention or antibody-drug conjugates (Antibody-Drug Conjugate, ADC); or administering a pharmaceutically effective amount of a Chimeric Antigen Receptor (CAR) to a subject, for example, immune-related diseases; Or it relates to a method for preventing or treating a brain nervous system disease.
- ADC Antibody-Drug Conjugate
- CAR Chimeric Antigen Receptor
- the “immune-related disease” of the present invention may be at least one selected from the group consisting of autoimmune disease, graft-versus-host disease, organ transplant rejection, asthma, atopy, and acute or chronic inflammatory disease, but is limited thereto It is not.
- the autoimmune disease of the present invention is rheumatoid arthritis, systemic scleroderma, systemic lupus erythematosus, atopic dermatitis, psoriasis, alopecia areata, asthma, Crohn's disease, Behçetsi disease, Sjögren's syndrome, Guilla-Barré syndrome, chronic thyroiditis, multiple sclerosis , polymyositis, ankylosing spondylitis, fibromyalgia, and polyarteritis nodosa, but may be at least one selected from the group consisting of, but is not limited thereto.
- “Cranial nervous system disease” for preventing, improving or treating the composition provided in the present invention may be a neurodegenerative disease or a neuroinflammatory disease.
- neurodegenerative disease and “neuroinflammatory disease” of the present invention include stroke, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, Niemann-Pick disease , prion disease, Creutzfeldt-Jakob disease, frontotemporal dementia, Lewy dementia, AlzAmyotrophic lateral sclerosis, Paraneoplastic syndrome, corticobasal degeneration, Select from the group consisting of systemic atrophy, progressive supranuclear palsy, autoimmune disease of the nervous system, spinocerebellar ataxia, inflammatory and neuropathic pain, cerebrovascular disease, spinal cord injury and tauopathy It may be, but is not limited thereto.
- the antibody-drug conjugate specifically binds to an epitope comprising a polypeptide represented by any one of the amino acid sequences of SEQ ID NOs: 35 to 45 to regulate the function of the regulatory T cell and regulate the activity of the effector T cell, thereby producing various The disease can be treated very effectively.
- the "individual” is an individual suspected of having an immune-related disease or a brain nervous system disease
- the subject suspected of having an immune-related disease or a brain nervous system disease is a mouse, including a human who has or may develop the disease, It refers to mammals including livestock, etc., but subjects that can be treated with the antibody, antigen-binding fragment or antibody-drug conjugate of the present invention are included without limitation.
- the method of the present invention may include administering a pharmaceutically effective amount of an antibody or antibody-drug conjugate.
- An appropriate total daily amount can be determined by a treating physician within the scope of sound medical judgment, and can be administered once or divided into several times.
- a specific therapeutically effective amount for a particular patient is determined by the type and extent of the response to be achieved, the specific composition, including whether other agents are used as the case may be, the patient's age, weight, general state of health, It is preferable to apply differently according to various factors including gender and diet, administration time, administration route and secretion rate of the composition, treatment period, drugs used together with or concurrently used with a specific composition, and similar factors well known in the medical field.
- the method for preventing or treating the disease may be a combination therapy further comprising administering a compound or substance having therapeutic activity for one or more diseases.
- the "combination" should be understood to denote simultaneous, separate or sequential administration.
- the interval between administrations of the second components should be such that the beneficial effects of the combination are not lost.
- the administration dose of the antibody or antibody-drug conjugate may be about 0.0001 ⁇ g to 500 mg per 1 kg of patient body weight, but is not limited thereto.
- Covalent Labeling MS CL-MS
- XL-MS Cross-linking MS
- the protein used in the screening method of the present invention may be a form displayed on the cell surface, a form displayed on the surface of a virus (eg, bacteriophage), an isolated form, or a purified form. there is.
- a protein displayed on the surface of a cell or virus it is preferable to immobilize the cell or virus on a solid substrate for expedited or automated screening.
- immobilize the protein in an isolated or purified form on a solid substrate Any material commonly used in the art may be used as the substrate, and examples thereof include, but are not limited to, hydrocarbon polymers such as polystyrene and polypropylene, glass, metal, and gel.
- Solid phase substrates can be provided in the form of dipsticks, microtiter plates, particles (eg beads), affinity columns and immunoblot membranes (eg polyvinylidene fluoride membranes). Most preferably, the solid substrate is a microtiter plate.
- the screening method of the present invention can be carried out in various ways, and in particular, it can be carried out in a high throughput manner according to various binding assays known in the art.
- the test substance or the proteins may be labeled with a detectable label.
- the detectable label may be a chemical label (e.g., biotin), an enzyme label (e.g., horseradish peroxidase, alkaline phosphatase, peroxidase, luciferase, ⁇ -galacto) sidase and ⁇ -glucosidase), radioactive labels (e.g., C14, I125, P32 and S35), fluorescent labels (e.g., coumarin, fluorescein, fluoresein isothiocyanate (FITC), rhodamine 6G, rhoda Min B (rhodamine B), TAMRA (6-carboxy-tetramethyl-rhodamine), Cy-3, Cy-5, Texas Red, Alexa Fluor, DAPI (4,6-diamidino-2phenylindole), HEX, TET, Dabsyl and FAM
- a chemical label e.g
- the occurrence of binding between the protein and the test substance can be analyzed by detecting a signal from the label.
- alkaline phosphatase bromochloroindolyl phosphate (BCIP), nitro blue tetrazolium (NBT), naphthol-AS-B1-phosphate (naphthol-AS-B1-phosphate ) and chromogenic substrates such as ECF (enhanced chemifluorescence) to detect signals.
- BCIP bromochloroindolyl phosphate
- NBT nitro blue tetrazolium
- naphthol-AS-B1-phosphate naphthol-AS-B1-phosphate
- chromogenic substrates such as ECF (enhanced chemifluorescence)
- an epitope of Lrig-1 (leucine-rich and immunoglobulin-like domains 1) protein at least one selected from the group consisting of polypeptides consisting of amino acid sequences represented by SEQ ID NO: 35 to SEQ ID NO: 45 Provides an epitope comprising a polypeptide of
- polypeptide provides an epitope, consisting of the amino acid sequence represented by SEQ ID NO: 38 or 44.
- the polypeptide provides an epitope consisting of the amino acid sequences represented by SEQ ID NOs: 35 to 37, 39 to 43, and 45.
- Another embodiment of the present invention provides a nucleic acid molecule encoding the epitope.
- Another embodiment of the present invention provides an expression vector into which the nucleic acid molecule is inserted.
- the expression vector provides a host cell line transfected
- One embodiment of the present invention provides a binding molecule that specifically binds to an epitope containing at least one polypeptide selected from the group consisting of polypeptides consisting of the amino acid sequences represented by SEQ ID NO: 35 to SEQ ID NO: 45.
- Another embodiment of the present invention provides a binding molecule, wherein the binding molecule is an antibody or a fragment thereof.
- the antibody is a chimeric antibody, a humanized antibody, a bivalent, a bispecific molecule, a minibody, a domain antibody, a bispecific antibody, or an antibody mimetic. , a diabody, a triabody, a tetrabody, or a fragment thereof, to provide a binding molecule.
- the antigen-specific binding domains are SEQ ID NOs: 35 to 45
- An antigen-specific binding domain that specifically binds to an epitope comprising at least one polypeptide selected from the group consisting of polypeptides consisting of the amino acid sequence shown; and a chimeric antigen receptor which is a fusion protein comprising an immunoglobulin Fc region.
- Another embodiment of the present invention provides an antibody-drug conjugate comprising the above binding molecule and drug.
- Another embodiment of the present invention provides a pharmaceutical composition for preventing or treating immune-related diseases comprising any one of the binding molecule, chimeric antigen receptor, and antibody-drug conjugate as an active ingredient.
- the immune-related disease is at least one selected from the group consisting of autoimmune disease, graft-versus-host disease, organ transplant rejection, asthma, atopy, and acute or chronic inflammatory disease. It provides a pharmaceutical composition for preventing or treating related diseases.
- a pharmaceutical composition for preventing or treating brain nervous system diseases comprising any one of the binding molecule, the chimeric antigen receptor, and the antibody-drug conjugate as an active ingredient.
- the brain nervous system disease is a neurodegenerative disease or a neuroinflammatory disease, provides a pharmaceutical composition.
- the neurodegenerative disease or neuroinflammatory disease is stroke, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, Niemann-Pick disease , prion disease, Creutzfeldt-Jakob disease, frontotemporal dementia, Lewy dementia, AlzAmyotrophic lateral sclerosis, Paraneoplastic syndrome, corticobasal degeneration, Selected from the group consisting of systemic atrophy, progressive supranuclear palsy, autoimmune disease of the nervous system, spinocerebellar ataxia, inflammatory and neuropathic pain, cerebrovascular disease, spinal cord injury and tauopathy It provides a pharmaceutical composition for the prevention or treatment of at least one, neurodegenerative disease or neuroinflammatory disease.
- Another embodiment of the present invention provides a method for screening a protein epitope of Lrig-1 (leucine-rich and immunoglobulin-like domains 1) comprising the following steps.
- (a) preparing an antibody comprising the heavy chain region represented by the amino acid sequence of SEQ ID NO: 17 and the light chain region represented by the amino acid sequence of SEQ ID NO: 18 or the heavy chain region represented by the amino acid sequence of SEQ ID NO: 19, SEQ ID NO: 20 Preparing an antibody comprising a light chain region represented by the amino acid sequence of or preparing an antibody comprising a heavy chain region represented by the amino acid sequence of SEQ ID NO: 21 and a light chain region represented by the amino acid sequence of SEQ ID NO: 22
- Another embodiment of the present invention provides a method for screening an epitope of Lrig-1 protein using the antibody.
- Another embodiment of the present invention provides a method for screening a binding molecule that is an antibody or a fragment thereof using the epitope.
- Another embodiment of the present invention provides a method for binding the epitope with a binding molecule that is an antibody or a fragment thereof.
- a binding molecule that is an antibody or a fragment thereof that specifically binds to Lrig-1 (leucine-rich and immunoglobulin-like domains 1) protein,
- the heavy chain variable region (VH) of the binding molecule comprises: the amino acid sequence represented by SEQ ID NOs: 46, 52, 58, 64, 70, 76, 82 and 88; Heavy chain variable region (VH) CDR1 selected from the group consisting of; a heavy chain variable region (VH) CDR2 selected from the group consisting of the amino acid sequences represented by SEQ ID NOs: 47, 53, 59, 65, 71, 77, 83 and 89; and a heavy chain variable region (VH) CDR3 selected from the group consisting of amino acid sequences represented by SEQ ID NOs: 48, 54, 60, 66, 72, 78, 84 and 90; and
- VL light chain variable region
- VL light chain variable region
- Heavy chain variable region (VL) CDR1 selected from the group consisting of; a heavy chain variable region (VL) CDR2 selected from the group consisting of the amino acid sequences represented by SEQ ID NOs: 50, 56, 62, 68, 74, 80, 86 and 92; and a heavy chain variable region (VL) CDR3 selected from the group consisting of amino acid sequences represented by SEQ ID NOs: 51, 57, 63, 69, 75, 81, 87 and 93; ego
- the binding molecule provides a binding molecule that specifically binds to an epitope containing at least one polypeptide selected from the group consisting of polypeptides consisting of the amino acid sequences represented by SEQ ID NO: 35 to SEQ ID NO: 45.
- the antibody or antigen-binding fragment specifically binding to the epitope of Lrig-1 protein according to the present invention inhibits the function of regulatory T cells by specifically binding to the epitope of the present invention present on regulatory T cells, and By maintaining or increasing the activity of T cells, it can be used very efficiently for the prevention, improvement or treatment of various diseases.
- FIG 1 shows the structure of Lrig-1 protein according to an embodiment of the present invention.
- FIG. 2 shows the structure of Lrig-1 protein according to an embodiment of the present invention.
- Figure 3 shows the expression level of Lrig-1 mRNA according to an embodiment of the present invention.
- Figure 4 shows the expression level of Lrig-1 mRNA according to an embodiment of the present invention.
- FIG. 5 shows the expression level of Lrig-1 mRNA according to an embodiment of the present invention.
- FIG. 6 shows the expression levels of Lrig-1, Lrig-2 and Lrig-3 mRNA according to an embodiment of the present invention.
- FIG. 7 shows results of comparing the expression level of Lrig-1 protein in regulatory T cells and non-regulatory T cells according to an embodiment of the present invention.
- FIG 8 shows the expression of Lrig-1 protein on the surface of regulatory T cells according to an embodiment of the present invention.
- FIG. 9 is a diagram showing antibodies (GTC210-01, GTC210-02, GTC210-03, GTC210-04, GTC110-01, GTC110-02, GTC110-03 and GTC110-04) and Lrig-1 protein in one embodiment of the present invention. It shows the result of analyzing the binding force for .
- FIG. 10 shows monoclonal antibodies (GTC210-01, GTC210-02, GTC210-03, GTC210-04, GTC110-01, GTC110-02, GTC110-03 and GTC110) specific for the Lrig-1 protein in an embodiment of the present invention. -04) and the regulatory mechanism of Lrig-1 protein-induced Stat3 phosphorylation in regulatory T cells.
- FIG. 11 shows the result of confirming the weight loss after intraperitoneal injection of the monoclonal antibody according to the present invention to the inflammatory bowel disease animal model according to an embodiment of the present invention.
- FIG. 12 shows an experimental design diagram for producing a multiple sclerosis animal model according to an embodiment of the present invention.
- FIG. 13 is a graph showing the treatment effect evaluation score after injecting the monoclonal antibody according to the present invention into an animal model of multiple sclerosis according to an embodiment of the present invention.
- FIG. 14 is a graph showing the treatment effect evaluation score after injecting the monoclonal antibody according to the present invention into an animal model for multiple sclerosis according to an embodiment of the present invention.
- Figure 15 shows that it was confirmed that demyelination was remarkably reduced when the antibody according to an embodiment of the present invention was administered.
- helper T cell 1 CD4+ T-bet+
- helper T cell 17 CD4+ RoR ⁇ t+
- regulatory T cell CD4+ Foxp3+
- various inflammatory cytokines IFN-gamma, IL-17A
- anti-inflammatory cytokine IL-10 increased expression.
- FIG. 17 to 20 are Y-maze test (FIG. 17), novel object, treatment effect by injection of monoclonal antibody according to the present invention in each group (G1 to G4) of Alzheimer's animal model according to an embodiment of the present invention.
- FIG. 21 to 23 show peptides degraded by treatment with proteases (chymotrypsin (FIG. 21), trypsin (FIG. 22) and Asp-N/Lys-C (FIG. 23)) according to an embodiment of the present invention. It shows the results confirmed through the labeling analysis.
- proteases chymotrypsin (FIG. 21), trypsin (FIG. 22) and Asp-N/Lys-C (FIG. 23)
- 24 and 25 show the results of aligning and comparing peptides degraded by each protease according to an embodiment of the present invention based on sequences identified by covalant labeling analysis.
- FIG. 26 and 27 show the results of cross-linking analysis of peptides digested by treatment with proteases (chymotrypsin (FIG. 26) and trypsin (FIG. 27)) according to an embodiment of the present invention.
- 28 and 29 show the results of aligning and comparing peptides degraded by each protease according to an embodiment of the present invention based on sequences identified by cross-linking analysis.
- FIG. 30 shows the results of aligning and analyzing epitopes identified by covalant labeling and cross-linking analysis according to an embodiment of the present invention.
- the present invention relates to an epitope of Lrig-1 (leucine-rich and immunoglobulin-like domains 1) protein, which is an antigen present on the surface of regulatory T cells, and an antibody or antigen-binding fragment specifically binding thereto.
- Lrig-1 leucine-rich and immunoglobulin-like domains 1
- an epitope of the Lrig-1 (leucine-rich and immunoglobulin-like domains 1) protein comprising the amino acid sequence represented by SEQ ID NOs: 38, 39, 41, 42, 44 and 45
- An epitope selected from the group consisting of polypeptides is provided.
- a binding molecule that specifically binds to an epitope containing at least one polypeptide selected from the group consisting of polypeptides consisting of the amino acid sequences represented by SEQ ID NO: 35 to SEQ ID NO: 45 is provided. .
- the antigen-specific binding domain is SEQ ID NO: 35 to SEQ ID NO: 35
- An antigen-specific binding domain that specifically binds to an epitope comprising at least one polypeptide selected from the group consisting of polypeptides consisting of the amino acid sequence represented by 45; and a chimeric antigen receptor which is a fusion protein comprising an immunoglobulin Fc region.
- binding molecule that is an antibody or a fragment thereof that specifically binds to the Lrig-1 (leucine-rich and immunoglobulin-like domains 1) protein
- the heavy chain variable region (VH) of the binding molecule comprises: the amino acid sequence represented by SEQ ID NOs: 46, 52, 58, 64, 70, 76, 82 and 88; Heavy chain variable region (VH) CDR1 selected from the group consisting of; a heavy chain variable region (VH) CDR2 selected from the group consisting of the amino acid sequences represented by SEQ ID NOs: 47, 53, 59, 65, 71, 77, 83 and 89; and a heavy chain variable region (VH) CDR3 selected from the group consisting of amino acid sequences represented by SEQ ID NOs: 48, 54, 60, 66, 72, 78, 84 and 90; and
- VL light chain variable region
- VL light chain variable region
- Heavy chain variable region (VL) CDR1 selected from the group consisting of; a heavy chain variable region (VL) CDR2 selected from the group consisting of the amino acid sequences represented by SEQ ID NOs: 50, 56, 62, 68, 74, 80, 86 and 92; and a heavy chain variable region (VL) CDR3 selected from the group consisting of amino acid sequences represented by SEQ ID NOs: 51, 57, 63, 69, 75, 81, 87 and 93; ego
- the binding molecule provides a binding molecule that specifically binds to an epitope containing at least one polypeptide selected from the group consisting of polypeptides consisting of the amino acid sequences represented by SEQ ID NO: 35 to SEQ ID NO: 45.
- T cell subsets such as Th0, Th1, Th2, Th17 and iTreg were prepared.
- the iTreg refers to cells artificially induced to differentiate in a medium containing the following composition.
- T cells As for the subtype of T cells, first, naive T cells obtained from the spleen of mice were isolated, and RPMI1640 (Invitrogen Gibco, Grand Island, NY) containing 10% fetal bovine serum (FBS; hyclone, logan, UT) was used. Differentiation was induced into each cell through 72-hour culture in a 37°C, 5% CO 2 incubator by further including the components of Table 1 below in the nutrient medium, respectively.
- FBS fetal bovine serum
- LRR1 to LRR15 were present in the Lrig-LRR domain (amino acid sequences 41 to 494) among the extracellular domains of the Lrig-1 protein.
- LRR domains consisted of 23 to 27 amino acids, and 3 to 5 leucines were present.
- Lrig-1 protein could act as a biomarker specific to regulatory T cells.
- CD4 + T cells were isolated from the spleen of mice using CD4 beads using magnet-activated cell sorting (MACS). Thereafter, regulatory T (CD4 + CD25 + T) cells and non-regulatory T (CD4 + CD25 - T) cells were isolated using a fluorescence-activated cell sorter (FACS) using the CD25 antibody.
- FACS fluorescence-activated cell sorter
- mRNA was extracted from each cell and the cells differentiated in Preparation Example 1 using Trizol, and gDNA was removed from genomic RNA using a gDNA extraction kit (Qiagen) according to the protocol provided by the company. .
- mRNA from which gDNA was removed was synthesized into cDNA using the BDsprint cDNA synthesis kit (Clonetech).
- the real-time polymerase chain reaction was carried out using SYBR Green (Molecular Probes) under the conditions of 40 cycles of 3 minutes at 95 ° C, 15 seconds at 61 ° C, and 30 seconds at 72 ° C according to the protocol provided by the company. It was performed using primers, and the relative gene expression level was calculated using the ⁇ CT method, and normalized using HPRT, and the results are shown in FIGS. 3 to 6.
- Lrig-1 is 18.1 times higher in regulatory T (CD4 + CD25 + T) cells than in non-regulatory T (CD4 + CD25 - T) cells. This level was about 10 times higher than that of Lag3 and Ikzf4, which are known markers of regulatory T cells.
- regulatory T cells are higher than those of other types of immune cells. Expression of Lrig-1 mRNA was significantly higher in cells, especially in naturally isolated regulatory T cells (nTreg) compared to induced regulatory T cells (iTreg).
- Lrig-1 was the highest among Lrig-1, Lrig-2, and Lrig-3 corresponding to the Lrig family.
- the Lrig-1 protein according to the present invention is specifically expressed in regulatory T cells, particularly in naturally occurring regulatory T cells.
- Lrig-1 protein expressed from Lrig-1 mRNA was specifically expressed only in regulatory T cells.
- non-regulatory T cells indicated by dotted lines showed almost the same level of Lrig-1 as that of the negative control group, but many regulatory T cells showed high levels of Lrig-1.
- the Lrig-1 protein according to the present invention is specifically expressed in regulatory T cells.
- Lrig-1 protein In order for Lrig-1 protein to be a target for cell therapy, it must be expressed on the surface of regulatory T cells for more effective targeted therapy. Therefore, whether Lrig-1 protein was expressed on the surface was checked.
- Each differentiated T cell subtype of Preparation Example 1 was stained with anti-CD4-APC and anti-Lrig-1-PE antibodies, and each cell surface was stained using a fluorescence-activated cell sorter (FACS). The expression level of Lrig-1 was measured in , and the results are shown in FIG. 8 .
- FACS fluorescence-activated cell sorter
- Lrig-1 was expressed in an amount of 0.77 to 15.3 in activated T cells, Th1 cells, Th2 cells, Th17 cells, and Naive T cells, whereas differentiation was expressed as high as 83.9 in induced T cells (iTreg).
- the Lrig-1 protein according to the present invention is not only specifically expressed in regulatory T cells (Treg) cells, but also has a higher level of expression, particularly on the surface of regulatory T cells.
- An antibody specific to the Lrig-1 protein according to the present invention was prepared. This antibody was not produced by specifying a specific antigenic determinant, but an antibody capable of binding to any site on the Lrig-1 protein was produced.
- the antibody cells expressing the Lrig-1 protein were prepared. More specifically, the DNA fragment corresponding to SEQ ID NO: 2 and pcDNA (hygro) are cut with a cutting enzyme, incubated at 37 ° C., and then ligated to insert the DNA sequence of the Lrig-1 protein The prepared pcDNA was prepared. The prepared pcDNA into which SEQ ID NO: 2 was inserted was introduced into L cells through transfection so that Lrig-1 protein could be expressed on the surface of L cells.
- Light chain and heavy chain amino acid sequences capable of binding to Lrig-1 expressed on the cell surface were selected from the Human scFv library, and a total of 8 heavy and light chains were selected.
- a monoclonal antibody was prepared by fusing the selected heavy and light chain amino acid sequences with the mlgG2a Fc region or the human IgG1 Fc region.
- the sequences of the monoclonal antibodies are shown in Table 3 below.
- Preparation Examples 1 to 9 recognize Lrig-1 well, the antibodies of Preparation Examples 1 to 9 are bound to L cells stably expressing Lrig-1. After that, a secondary antibody capable of recognizing the mouse antibody and conjugated to eFlour 670 was added, and then the binding ability of the above preparations to the Lrig-1 protein was analyzed using FACS to help the result. 9.
- Preparation Examples 1 to 9 affect the signal transduction pathway in regulatory T cells through the Lrig-1 protein
- the monoclonal antibodies corresponding to Preparation Examples 1 to 9 After treating regulatory T cells with antibodies to stimulate Lrig-1 present on the surface of regulatory T cells, tyrosine phosphorylation of Stat3 protein present in stimulated regulatory T cells was performed by phosphotyrosine immunoblot ( tyrosine phosphorylation) was analyzed, and the results are shown in FIG. 10 .
- the Lrig-1 protein-specific monoclonal antibodies (GTC210-01, GTC210-02, GTC210-03 and GTC210-04) according to the present invention showed the same level of phosphorylation of Stat3 as that of Th17 cells. It was confirmed that an increase in On the other hand, Lrig-1 protein-specific monoclonal antibodies (GTC110-01, GTC110-02, GTC110-03 and GTC110-04) according to the present invention continuously maintain Stat3 phosphorylation at the same level as iTreg cells and reduction was observed.
- autoimmune diseases of Preparation Examples 1 to 4 which are monoclonal antibodies according to the present invention
- CD45RB (high) cells were adoptively transplanted into RAG-1 -/- mice to autoimmune diseases.
- IBD inflammatory bowel disease
- the antibodies of Preparation Examples 1 to 4 were intraperitoneally injected in an amount of 200 ⁇ g/mouse, and then the treatment effect of autoimmune disease was analyzed, and the results are shown in FIG. 11 shown in
- the Lrig-1 protein-specific monoclonal antibodies (GTC210-01, GTC210-02, GTC210-03 and GTC210-04) according to the present invention significantly reduce body weight in inflammatory bowel disease-induced mice. inhibition could be confirmed.
- the Lrig-1 protein-specific monoclonal antibody according to the present invention can treat autoimmune diseases, graft-versus-host diseases, organ transplant rejection, asthma, It can be seen that immune-related diseases such as atopy or acute or chronic inflammatory diseases can be effectively prevented, improved or treated.
- mice were subcutaneously injected with MOG peptide and intraperitoneally injected with Mycobacterium tuberculosis toxin.
- MOG peptide intraperitoneally injected with Mycobacterium tuberculosis toxin.
- another injection of Mycobacterium tuberculosis toxin was given to boost the immune system of the mice.
- mice were administered the GTC210-01 antibody prepared in Preparation Example 1, and anti-IL-17a antibody was administered as a positive control.
- mice is immobile, but one forelimb is responsive to stimulation
- mice were subcutaneously injected with MOG peptide and intraperitoneally injected with Mycobacterium tuberculosis toxin.
- MOG peptide intraperitoneally injected with Mycobacterium tuberculosis toxin.
- another injection of Mycobacterium tuberculosis toxin was given to boost the immune system of the mice.
- mice On the 2nd, 4th, and 6th day, it was administered to mice at a concentration of 5mg/kg of the GTC210-03 antibody prepared in Preparation Example 3.
- mice is immobile, but one forelimb is responsive to stimulation
- Roxol Fast Blue was also put in xylene to deparaffinize, and then xylene was removed using 100% alcohol, followed by Roxol Fast Blue for the nerve tissue of the mouse. After staining with blue (Luxol Fast Blue) at 60° C. for 16 to 24 hours, followed by differential discoloration (differentiator), the results are shown in FIG. 15 .
- an immune-related disease that is, an autoimmune disease
- an experimental autoimmune encephalomyelitis (EAE) mouse disease model was used.
- Splenocytes of mice treated with the GTC210-03 antibody of Preparation Example 3 were isolated and CD4 T cells were reactivated.
- the mouse since the mouse has already been exposed to the antigen in the body, when stimulated again outside the body, stronger activity occurs, and the differentiated CD4 T cells secrete their own representative cytokines.
- cells were obtained on the 10th day after disease induction and reactivated for 48 hours with 40 ⁇ g/ml of MOG peptide. Then, the amount of cytokines present in the culture medium was confirmed by ELISA.
- helper T cell 1 CD4+ T-bet+
- helper T cell 17 CD4+ RoR ⁇ t+
- regulatory T cells CD4+ Foxp3+
- various inflammatory cytokines IFN-gamma, IL-17A
- anti-inflammatory cytokines IL-10 increased expression.
- the GTC210-03 antibody of Preparation Example 3 that specifically binds to the epitope according to the present invention when administered, it suppresses the expression of “inflammatory” cytokines as well as the expression of IL-10, an “anti-inflammatory” cytokine It was confirmed that the inflammatory response was eventually suppressed by increasing
- mice 7-month-old Alzheimer's-induced 5xFAD mice (known to exhibit amyloid deposits, gliosis, and progressive neuronal loss with cognitive and motor deficits) were injected with GTC110-04 mouse antibody and GTC210-01 antibody at an amount of 10 mpk each. Injected intravenously for 1 month.
- GTC110-04 mouse antibody As a positive control, 8-month-old Alzheimer's mice were subcutaneously injected with 100 ⁇ g of glatiramer acetate (GA, Copaxone®) for 3 weeks.
- GA glatiramer acetate
- mice of the group were treated with a Y-maze test, a Novel Object Recognition test, and a Water maze test.
- a maze frame made by arranging the same three arms with a length of 40 cm (height of the wall 15 cm) at an angle of 120 degrees was used.
- This experiment was a behavioral experiment using rodents' instinctive search habits, and it was a method that focused on the high possibility of exploring new areas.
- the arm that was searched just before was memorized, and the higher the level of memory was displayed, the more they did not enter the same arm.
- a search time of 8 minutes was provided per subject, and the final result was expressed as a spontaneous alteration (%) value in FIG. 17 .
- the spontaneous alteration (%) value was calculated by Equation 1 below.
- the behavioral pattern analysis was performed using SMART VIDEO TRACKING Software (Panlab, USA), and the results are shown in FIG. 17 .
- Alzheimer's-induced mice were treated with the antibodies according to the present invention (GTC210-01 and GTC110-04 antibodies). When administered, it was confirmed that the spontaneous shift value was similar to that of the normal control group.
- the normal control group (G1) was 0.51 ⁇ 0.06
- the G2 group (vehicle) was measured as 0.42 ⁇ 0.04
- the Alzheimer's induced group (G2) was measured as a normal control group.
- the preference value was observed to be lower.
- the antibodies according to the present invention GTC210-01 and GTC110-04 antibodies
- a probe test was conducted on the 6th day after swimming practice, and as spatial perception ability, the value calculated as a percentage of the total swimming time of the time spent in the quadrant where the platform was located (Percentage of time in SW area, %) , The time taken to reach the position where the platform was (Latency to target, sec) was measured, and the results are shown in FIGS. 19 and 20.
- analysis was performed using SMART VIDEO TRACKING Software (Panlab, USA). The criterion to exclude from the interpretation of the results was set as an individual turning only a specific part without searching through swimming.
- the time spent in the quadrant where the platform was located was calculated as a percentage of the total swimming time (Percentage of time in SW area, %) was significantly increased, and the time taken to reach the position where the platform was located (Latency to target, sec) significantly decreased to a level similar to that of the normal control group.
- IAA Iodoacetamide
- Syringe filter 0.2um (Sartorius stedim, 16534)
- the ratio of antigen and antibody was set to 2:1, and antigen samples were prepared. Then, DEPC was added so as not to exceed 1%, followed by reaction at 37 ° C. for 1 minute, and imidazole was added to complete the reaction. Then, after performing the precipitation reaction by adding acetone, the supernatant was removed by centrifugation, and the precipitate was well released using 0.1% PM. Trypsin, chymotrypsin, or Asp-N/Lys-C was added to the precipitate released in this manner to undergo degradation, and then sugar chains attached to proteins were removed using PNGase-F. Finally, disulfide bonds between cysteines of proteins were cleaved using DTT and IAA, and LC-MS and MS2 analysis were performed.
- the ratio of antigen and antibody was set to 2:1, and two antigen samples were prepared. Then, the cross linker (CSBU) was sufficiently dissolved in DMSO. Thereafter, the ratio of the sample and DSG was added to be 1:100, and only DMSO was added to the other, followed by reaction at 25 °C for 1 hour. After the reaction was completed, the protein was decomposed using trypsin or chymotrypsin, and sugar chains attached to the protein were removed using PNGase-F. Finally, disulfide bonds between cysteines of proteins were cleaved using DTT and IAA, and LC-MS and MS2 analysis were performed.
- CSBU cross linker
- Step total time (min) Flow rate ( ⁇ L/min) A(%) B(%) 0 0.00 100.00 95.0 5.0
- Control group huTregL1-his (Ag, Control) and test group huTregL1-his/E7-mlgG2a (Ag+Ab, Test) samples were treated with DEPC and then treated with trypsin, chymotrypsin or Asp-N/Lys-C to digest Each sample was analyzed three times repeatedly (see FIGS. 21 to 23).
- the MS analysis results of the control group (Control 1) and the test group (Test 1) shown in the above analysis results were matched with the sequence of the control group (huTregL1-his) using the BioPhama finder program, and the labeled peptides were compared.
- sequences E62-L101, D111-L134, and Q542-Y553 were 13.2%, 15.3%, and 14.7%, respectively, with a labeling decrease (%) of 10% or more.
- the E62-L101 sequence the E62-K92 part (AL) showed 65.9%, L65-F87 part (Y) 48.7%, and the L88-L101 part showed labeling (%) of 88.6%. From this result, it can be considered that the L88-L101 portion with labeling (%) of 50% or more among the E62-L101 sequences is exposed to the outside.
- the chymotrypsin-treated group showed a 15.3% labeling decrease (%), but it was confirmed that the control RSD was 62.4%.
- the Q542-Y553 sequence also showed a 14.7% labeling decrease (%) in the chymotrypsin-treated group, and the labeling (%) of the control antigen was 50% or more, which was judged to be an externally exposed portion in terms of protein structure.
- test group (huTregL1-his/E7-mlgG2a) mixture sample was prepared, the test group sample was treated with a cross-linker, disuccinimidyl dibutyric urea (DSBU), and the test group was treated with a protease (chymotrypsin or trypsin). Samples were disaggregated (FIGS. 27 and 28). Then, peptide sequences in which peptides digested with chymotrypsin and trypsin were not detected in the test tube (including 2% or less) were identified in comparison with the control group.
- DSBU disuccinimidyl dibutyric urea
- the peptide sequences not detected in the test group samples were combined and determined as the epitope site.
- the peptide ratio (T%) of the same sequence detected in the test group sample compared to the control group was confirmed to be 2% or less in both chymotrypsin or trypsin. .
- T158-F174 and G442-K476 were decreased in Chymotrypsin (Y) and Trypsin (T), respectively.
- S362-K365 of the Trypsin (T) treated group was the only sequence where T% was not detected (0%).
- T% was not detected (0%).
- the epitope was predicted by synthesizing the previous results. Specifically, two sequences of huTregL1-his (Ag), including E62-L101 and G452-K476, were identified as identical positions in CL-MS and XL-MS analysis results. Among the L62-L101, the L88-K92 part showed a labeling decrease (%) in the two protease treatment groups (Chymotrypsin, Asp-N/Lys-C) as a result of CL-MS, and in the XL-MS analysis, the two protease treatment groups ( Chymotrypsin, Trypsin) were significantly reduced.
- the S95-L101 portion In the case of the S95-L101 portion, it was an epitope overlappingly identified in chymotrypsin and trypsin in XL-MS. In addition, as a result of CL-MS, the L88-L101 portion with labeling (%) of 50% or more was exposed to the outside. In particular, in the case of L88-L101, the amino acid sequence in the sequence was composed of hydrophilic amino acids (Q89-S95) consecutively.
- the antibody or antigen-binding fragment specifically binding to the epitope of Lrig-1 protein according to the present invention inhibits the function of regulatory T cells by specifically binding to the epitope of the present invention present on regulatory T cells, and By maintaining or increasing the activity of T cells, it can be used very efficiently for the prevention, improvement or treatment of various diseases.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Computational Biology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
Abstract
Description
분화 세포 | 조성 |
Th0 | anti-CD3, anti-CD28 |
Th1 | IL-12, anti-IL-4 항체 |
Th2 | IL-4, anti-IFNβ |
Th17 | IL-6, TGFβ, anti-IFNβ, anti-IL-4 |
iTreg | IL-2, TGFβ |
프라이머 | 방향 | 서열번호 |
마우스 Lrig-1 | Forward | 서열번호 7 |
Reverse | 서열번호 8 | |
마우스 Lrig-2 | Forward | 서열번호 9 |
Reverse | 서열번호 10 | |
마우스 Lrig-3 | Forward | 서열번호 11 |
Reverse | 서열번호 12 | |
마우스 FOXP3 | Forward | 서열번호 13 |
Reverse | 서열번호 14 | |
ACTG1 | Forward | 서열번호 15 |
reverse | 서열번호 16 |
구분 | 클론 | 위치 | 서열정보 |
제조예 1 | GTC210-01 clone | 중쇄 | 서열번호 17 |
중쇄 CDR1 | 서열번호 46 | ||
중쇄 CDR2 | 서열번호 47 | ||
중쇄 CDR3 | 서열번호 48 | ||
경쇄 | 서열번호 18 | ||
경쇄 CDR1 | 서열번호 49 | ||
경쇄 CDR2 | 서열번호 50 | ||
경쇄 CDR3 | 서열번호 51 | ||
제조예 2 | GTC210-02 clone | 중쇄 | 서열번호 19 |
중쇄 CDR1 | 서열번호 52 | ||
중쇄 CDR2 | 서열번호 53 | ||
중쇄 CDR3 | 서열번호 54 | ||
경쇄 | 서열번호 20 | ||
경쇄 CDR1 | 서열번호 55 | ||
경쇄 CDR2 | 서열번호 56 | ||
경쇄 CDR3 | 서열번호 57 | ||
제조예 3 | GTC210-03 clone | 중쇄 | 서열번호 21 |
중쇄 CDR1 | 서열번호 58 | ||
중쇄 CDR2 | 서열번호 59 | ||
중쇄 CDR3 | 서열번호 60 | ||
경쇄 | 서열번호 22 | ||
경쇄 CDR1 | 서열번호 61 | ||
경쇄 CDR2 | 서열번호 62 | ||
경쇄 CDR3 | 서열번호 63 | ||
제조예 4 | GTC210-04 clone | 중쇄 | 서열번호 23 |
중쇄 CDR1 | 서열번호 64 | ||
중쇄 CDR2 | 서열번호 65 | ||
중쇄 CDR3 | 서열번호 66 | ||
경쇄 | 서열번호 24 | ||
경쇄 CDR1 | 서열번호 67 | ||
경쇄 CDR2 | 서열번호 68 | ||
경쇄 CDR3 | 서열번호 69 | ||
제조예 5 | GTC110-01 clone | 중쇄 | 서열번호 25 |
중쇄 CDR1 | 서열번호 70 | ||
중쇄 CDR2 | 서열번호 71 | ||
중쇄 CDR3 | 서열번호 72 | ||
경쇄 | 서열번호 26 | ||
경쇄 CDR1 | 서열번호 73 | ||
경쇄 CDR2 | 서열번호 74 | ||
경쇄 CDR3 | 서열번호 75 | ||
제조예 6 | GTC110-02 clone | 중쇄 | 서열번호 27 |
중쇄 CDR1 | 서열번호 76 | ||
중쇄 CDR2 | 서열번호 77 | ||
중쇄 CDR3 | 서열번호 78 | ||
경쇄 | 서열번호 28 | ||
경쇄 CDR1 | 서열번호 79 | ||
경쇄 CDR2 | 서열번호 80 | ||
경쇄 CDR3 | 서열번호 81 | ||
제조예 7 | GTC110-03 clone | 중쇄 | 서열번호 29 |
중쇄 CDR1 | 서열번호 82 | ||
중쇄 CDR2 | 서열번호 83 | ||
중쇄 CDR3 | 서열번호 84 | ||
경쇄 | 서열번호 30 | ||
경쇄 CDR1 | 서열번호 85 | ||
경쇄 CDR2 | 서열번호 86 | ||
경쇄 CDR3 | 서열번호 87 | ||
제조예 8 | GTC110-04 마우스 항체 | 중쇄 | 서열번호 31 |
중쇄 CDR1 | 서열번호 88 | ||
중쇄 CDR2 | 서열번호 89 | ||
중쇄 CDR3 | 서열번호 90 | ||
경쇄 | 서열번호 32 | ||
경쇄 CDR1 | 서열번호 91 | ||
경쇄 CDR2 | 서열번호 92 | ||
경쇄 CDR3 | 서열번호 93 | ||
제조예 9 | GTC110-04 인간화 항체 |
중쇄 | 서열번호 33 |
중쇄 CDR1 | 서열번호 88 | ||
중쇄 CDR2 | 서열번호 89 | ||
중쇄 CDR3 | 서열번호 90 | ||
경쇄 | 서열번호 34 | ||
경쇄 CDR1 | 서열번호 91 | ||
경쇄 CDR2 | 서열번호 92 | ||
경쇄 CDR3 | 서열번호 93 |
CDR | 위치 | 허용 변경 |
VH CDR1 | S1 | G, N, D |
D3 | Y, A | |
VH CDR2 | G1 | L, S, W, A, V |
S3 | Y | |
P4 | H | |
D5 | G, S | |
G6 | S, D, | |
S7 | G | |
N8 | S | |
I9 | K, T | |
VH CDR3 | V1 | G, D |
G2 | L, I | |
L3 | G, S | |
R4 | L, P, N | |
R6 | K, P, H | |
Y7 | T, W, L | |
E8 | G | |
A9 | L, R, V | |
S11 | Y | |
A12 | Y, D, S | |
Y13 | D, N | |
G14 | A | |
VL CDR1 | S1 | T |
G2 | D | |
S9 | N | |
Y11 | N, S, T, D | |
S13 | T, N, Y | |
VL CDR2 | S1 | D, A |
D2 | N | |
S3 | N | |
H4 | Q, N | |
VL CDR3 | A1 | G |
T2 | S, A | |
S5 | Y, D | |
N8 | S | |
G9 | A |
CDR | 서열 | 바뀐 서열 | 서열번호 |
VH CDR1 | SYDMS | - | 58 |
GYDMS | S1→G | 46 | |
NYYMS | S1→N, D3→Y | 52 | |
NYDMS | S1→N | 64 | |
DYDMS | S1→D | 70 | |
DYYMS | S1→D | 76 | |
NYAMS | S1→N, D3→A | 82 | |
NYAMS | S1→N, D3→A | 88 | |
VH CDR2 | GISPDGSNIYYADSVKG | - | 59 |
LIYPDSGNKYYADSVKG | G1→L, S3→Y, G6→S, S7→G, I9→K | 47 | |
GISPGDSSTYYADSVKG | D5→G, G6→D, N8→S, I9→T | 53 | |
SISPSSGSIYYADSVKG | G1→S, D5→S, G6→S, S7→G, N8→S | 65 | |
WISHGGGSIYYADSVKG | G1→W, P4→H, D5→G, S7→G, N8→S | 71 | |
GISHDSGSKYYADSVKG | P4→H, G6→S, S7→G, N8→S, I9→K | 77 | |
AIYPGGGSIYYADSVKG | G1→A, S3→Y, D5→G, S7→G, N8→S | 83 | |
VISHGGGSTYYADSVKG | G1→V, P4→H, D5→G, S7→G, N8→S, I9→T | 89 | |
VH CDR3 | VGLRCRYEACSYAYGMDV | - | 60 |
GLGLCKTGLCYYYDAMDV | V1→G, G2→L, L3→G, R4→L, R6→K, Y7→T, E8→G, A9→L, S11→Y, A13→Y, Y14→D, G15→A | 72 | |
DILPCPWGRCYYDYAMDV | V1→D, G2→I, R4→P, Y7→W, E8→G, A9→R, S11→Y, A13→D, G15→A | 84 | |
VISNCHLGVCYYSNGMDV | G2→I, L3→S, R4→N, R6→H, Y7→L, E8→G, A9→V, S11→Y, A13→S, Y14→N | 90 | |
HWTTFDY | - | 78 | |
DAGLSWAGAFDY | - | 48 | |
GLYSNPNEPFDY | D1→G, A2→L, G3→Y, L4→S, S5→N, W6→P, A7→N, G8→E, A9→P | 54 | |
DLDAFWRPSFDY | A2→L, G3→D, L4→A, S5→F, A7→R, G8→P, A9→S | 66 | |
VL CDR1 | SGSSSNIGSNYVS | - | 61 |
SGSSSNIGSNYVT | S13→T | 49 | |
TGSSSNIGSNYVS | S1→T | 55 | |
TGSSSNIGNNNVN | S1→T, S9→N, Y11→N, S13→N | 67 | |
TGSSSNIGNNSVT | S1→T, S9→N, Y11→S, S13→T | 73 | |
SGSSSNIGSNNVT | Y11→N, S13→T | 79 | |
SDSSSNIGSNTVS | G2→D, Y11→T | 85 | |
SGSSSNIGNNDVY | S9→N, Y11→D, S13→Y | 91 | |
VL CDR2 | SDSHRPS | - | 62 |
SDSHRPS | - | 50 | |
DDSQRPS | S1→D, H4→Q | 56 | |
SDSHRPS | - | 68 | |
ADNNRPS | S1→A, S3→N, H4→N | 74 | |
ANSNRPS | S1→A, D2→N, H4→N | 80 | |
ADNNRPS | S1→A, S3→N, H4→N | 86 | |
SDSQRPS | H4→Q | 92 | |
VL CDR3 | ATWDSSLNGYV | - | 63 |
GSWDYSLSAYV | A1→G, T2→S, S5→Y, N8→S, G9→A | 51 | |
GTWDYSLNGYV | A1→G, S5→Y | 57 | |
GSWDDSLSAYV | A1→G, T2→S, S5→D, N8→S, G9→A | 69 | |
AAWDSSLSAYV | T2→A, N8→S, G9→A | 75 | |
GAWDYSLSAYV | A1→G, T2→A, S5→Y, N8→S, G9→A | 81 | |
GTWDYSLSGYV | A1→G, S5→Y, N8→S | 87 | |
GTWDYSLSGYV | A1→G, S5→Y, N8→S | 93 |
그룹 | n/그룹 | 투여경로 | 용량 | ||
G1 | WT | 대조군 | 14 | - | - |
G2 | 5xFAD | 대조군 | 13 | - | - |
G3 | GTC110-04 항체 | 11 | IV | 10 mpk | |
G4 | GTC210-01 항체 | 11 | IV | 10 mpk | |
G5 | GA(양성 대조군) | 11 | SC | 100 ㎍ |
단계(Step) | 전체 시간(min) | 유속(㎕/min) | A(%) | B(%) |
0 | 0.00 | 100.00 | 95.0 | 5.0 |
1 | 5.00 | 100.00 | 95.0 | 5.0 |
8 | 7.00 | 100.00 | 90.0 | 10.0 |
3 | 48.00 | 100.00 | 70.0 | 30.0 |
4 | 55.00 | 100.00 | 5.0 | 95.0 |
5 | 65.00 | 100.00 | 5.0 | 95.0 |
6 | 66.00 | 100.00 | 95.00 | 5.0 |
7 | 71.00 | 100.00 | 95.00 | 5.0 |
HESI Source | |
시스가스 유량(Sheath gas flow rate) | 35 |
보조가스 유량(Aux gas flow rate) | 10 |
스윕가스 유량(Sweep gas flow rate) | 1 |
스프레이 전압(Spray voltage)(kV) | 3.5 |
스프레이 전류(Spray current)(μA) | - |
모세관 온도(Capillary temp.(℃) | 250 |
S-lens RF level | 50 |
보조가스 히터온도(Aux gas heater temp.(℃) | 200 |
General | |
실행시간(Runtime) | 0에서 71분 |
극성(Polarity) | 양성 |
기본충전상태(Default charge state) | 2 |
Full MS | |
해상도(Resolution) | 70,000 |
AGC target | 3.00E+06 |
Maximum IT | 100 ms |
스캔 범위(Scan range) | 200 to 2,000 m/z |
dd-MS2 / dd-SIM | |
해상도(Resolution) | 17,500 |
AGC targe | 1.00E+05 |
Maximum IT | 54 ms |
반복 횟수(Loop count) | 10 |
TopN | 10 |
Isolation window | 1.6 m/z |
(N)CE / stepped (N)CE | nce: 27 |
dd Settings | |
Minimum AGC target | 8.00E+04 |
강도 임계값(Intensity threshold) | 1.50E+05 |
Charge exclusion | Unassigned, 7, 8, >8 |
Peptide match | Preferred |
동위원소 제외(Exclude isotopes) | On |
Dynamic exclusion | 5.0 s |
Claims (20)
- Lrig-1(leucine-rich and immunoglobulin-like domains 1) 단백질의 에피토프로서,서열번호 38, 39, 41, 42, 44 및 45로 표시되는 아미노산 서열을 포함하는 폴리펩티드로 구성된 군에서 선택되는 에피토프.
- 제1항에 있어서,상기 폴리펩티드는 서열번호 35, 36, 37, 40, 43으로 표시되는 아미노산 서열로 이루어진, 에피토프.
- 제1항의 에피토프를 코딩하는 핵산 분자.
- 제3항의 핵산 분자가 삽입된 발현 벡터.
- 제4항의 발현 벡터가 형질 감염된 숙주 세포주.
- 서열번호 35 내지 서열번호 45로 표시되는 아미노산 서열로 이루어진 폴리펩티드로 구성된 군으로부터 선택되는 적어도 어느 하나의 폴리펩티드를 포함하는 에피토프에 특이적으로 결합하는 결합분자.
- 제 6항에 있어서,상기 결합 분자는 항체 또는 그 단편인, 결합 분자.
- 제 7항에 있어서,상기 항체는 키메라 항체, 인간화 항체(humanized antibody), 이가(bivalent), 양특이성 분자, 미니바디(minibody), 도메인 항체, 이중특이적 항체(bispecific antibody), 항체 모방체, 디아바디(diabody), 트리아바디(triabody), 테트라바디(tetrabody) 또는 이의 단편인, 결합 분자.
- 항원 특이적 결합 도메인, 연결 도메인 및 CD3 제타(ζ) 신호전달 도메인을 포함하는 키메라 항원 수용체(CAR)에서,상기 항원 특이적인 결합 도메인은 서열번호 35 내지 서열번호 45로 표시되는 아미노산 서열로 이루어진 폴리펩티드로 구성된 군으로부터 선택되는 적어도 어느 하나의 폴리펩티드를 포함하는 에피토프에 특이적으로 결합하는 항원 특이적인 결합 도메인; 및 면역글로불린(immunoglobulin) Fc 영역을 포함하는 융합 단백질인 키메라 항원 수용체.
- 제 6항의 결합분자 및 약물을 포함하는 항체-약물 결합체.
- 제 6항 내지 제8항 중 어느 한 항의 결합분자, 제 9항의 키메라 항원 수용체, 제 10항의 항체-약물 결합체 중 어느 하나를 유효 성분으로 포함하는 면역 관련 질환의 예방 또는 치료용 약학 조성물.
- 제 11항에 있어서,상기 면역 관련 질환은 자가면역질환, 이식편대숙주 질환, 장기이식거부반응, 천식, 아토피, 및 급성 또는 만성의 염증 질환으로 이루어진 군으로부터 선택되는 적어도 하나인 것인, 면역 관련 질환의 예방 또는 치료용 약학 조성물.
- 제 12항에 있어서,상기 자가면역질환은 류마티스성 관절염, 전신성 경피증, 전신 홍반성 낭창, 아토피 피부염, 건선, 원형탈모증, 천식, 크론씨병, 베체시병, 쇼그렌 증후군, 길리아-바레 증후군, 만성 갑상선염, 다발성 경화증, 다발성 근염, 강직성 척추염, 섬유조직염 및 결절성 다발성 동맥염으로 구성된 군으로부터 선택되는 적어도 하나인 것인, 면역 관련 질환의 예방 또는 치료용 약학 조성물.
- 제 6항 내지 제 8항 중 어느 한 항의 결합분자, 제 9항의 키메라 항원 수용체, 제 10항의 항체-약물 결합체 중 어느 하나를 유효 성분으로 포함하는 뇌신경계 질환의 예방 또는 치료용 약학 조성물.
- 제 14항에 있어서,상기 뇌신경계 질환은 신경 퇴행성 질환 또는 신경 염증성 질환인, 약학 조성물.
- 제 14항에 있어서,상기 신경 퇴행성 질환 또는 신경 염증성 질환은 뇌졸중, 치매, 알츠하이머병(Alzheimer's disease), 파킨슨병(Parkinson's disease), 헌팅턴병(Huntington's disease), 니만-피크병(Niemann-Pick disease), 프리온병(prion disease), 크로이펠츠-야콥병(Creutzfeldt-Jakob disease), 전두측두치매, 루이치매, 근위축성 측삭경화증(AlzAmyotrophic lateral sclerosis), 부신생물증후군(Paraneoplastic syndrome), 피질기저퇴행증, 다계통위축병, 진행성핵상마비, 신경계 자가면역질환, 척수 소뇌 실조(spinocerebellar ataxia), 염증성 및 신경병증성 통증, 뇌혈관 질환, 척수 손상(spinal cord injury) 및 타우병증(tauopathy)으로 이루어진 군으로부터 선택되는 적어도 하나인 것인, 신경 퇴행성 질환 또는 신경 염증성 질환의 예방 또는 치료용 약학 조성물.
- 제 1항 또는 제 2항의 에피토프를 이용하여 항체 또는 그 단편인 결합 분자를 스크리닝 하는 방법.
- 제 6항의 항체를 이용하여 Lrig-1 단백질의 에피토프를 스크리닝 하는 방법.
- 제 1항 또는 제 2항의 에피토프와 항체 또는 그 단편인 결합 분자를 결합하는 방법.
- Lrig-1(leucine-rich and immunoglobulin-like domains 1) 단백질에 특이적으로 결합하는 항체 또는 그 단편인 결합 분자로서,(a) 상기 결합 분자의 중쇄 가변 영역(VH)은 다음을 포함하는 결합 분자의 중쇄 가변 영역(VH):서열번호 46, 52, 58, 64, 70, 76, 82 및 88로 표시되는 아미노산 서열로 이루어진 군에서 선택되는 중쇄 가변 영역(VH) CDR1;서열번호 47, 53, 59, 65, 71, 77, 83 및 89로 표시되는 아미노산 서열로 이루어진 군에서 선택되는 중쇄 가변 영역(VH) CDR2; 및서열번호 48, 54, 60, 66, 72, 78, 84 및 90으로 표시되는 아미노산 서열로 이루어진 군에서 선택되는 중쇄 가변 영역(VH) CDR3; 및(b) 상기 결합 분자의 경쇄 가변 영역(VL)은 다음을 포함하는 결합 분자의 경쇄 가변 영역(VL):서열번호 49, 55, 61, 67, 73, 79, 85 및 91로 표시되는 아미노산 서열로 이루어진 군에서 선택되는 중쇄 가변 영역(VL) CDR1;서열번호 50, 56, 62, 68, 74, 80, 86 및 92로 표시되는 아미노산 서열로 이루어진 군에서 선택되는 중쇄 가변 영역(VL) CDR2; 및서열번호 51, 57, 63, 69, 75, 81, 87 및 93으로 표시되는 아미노산 서열로 이루어진 군에서 선택되는 중쇄 가변 영역(VL) CDR3; 이고상기 결합 분자는 서열번호 35 내지 서열번호 45로 표시되는 아미노산 서열로 이루어진 폴리펩티드로 구성된 군에서 선택되는 적어도 어느 하나의 폴리펩티드를 포함하는 에피토프에 특이적으로 결합하는 결합 분자.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22842474.3A EP4375670A1 (en) | 2021-07-16 | 2022-07-14 | Epitope of regulatory t cell surface antigen, and antibody specifically binding thereto |
CN202280050296.0A CN117716238A (zh) | 2021-07-16 | 2022-07-14 | 调节性t细胞表面抗原的表位及其特异性结合的抗体 |
US18/413,322 US20240141036A1 (en) | 2021-07-16 | 2024-01-16 | Epitope of Regulatory T Cell Surface Antigen, and Antibody Specifically Binding Thereto |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0093657 | 2021-07-16 | ||
KR20210093657 | 2021-07-16 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/413,322 Continuation-In-Part US20240141036A1 (en) | 2021-07-16 | 2024-01-16 | Epitope of Regulatory T Cell Surface Antigen, and Antibody Specifically Binding Thereto |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023287212A1 true WO2023287212A1 (ko) | 2023-01-19 |
Family
ID=84920240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/010262 WO2023287212A1 (ko) | 2021-07-16 | 2022-07-14 | 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240141036A1 (ko) |
EP (1) | EP4375670A1 (ko) |
KR (1) | KR20230016148A (ko) |
CN (1) | CN117716238A (ko) |
WO (1) | WO2023287212A1 (ko) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
KR20180117066A (ko) * | 2017-04-18 | 2018-10-26 | 주식회사 굳티셀 | Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도 |
KR20190027808A (ko) * | 2019-03-08 | 2019-03-15 | 주식회사 굳티셀 | 조절자 T 세포에 특이적으로 존재하는 새로운 표면단백질 Lrig-1의 용도 |
KR20200112745A (ko) * | 2019-03-20 | 2020-10-05 | 주식회사 굳티셀 | 뇌신경계 질환의 예방 또는 치료용 조성물 |
KR20210056280A (ko) * | 2019-11-08 | 2021-05-18 | 주식회사 굳티셀 | 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체 |
KR20210075117A (ko) * | 2018-10-05 | 2021-06-22 | 세인트 안나 킨더크렙스포르슝 | 키메라 항원 수용체(car) 그룹 |
-
2022
- 2022-07-14 WO PCT/KR2022/010262 patent/WO2023287212A1/ko active Application Filing
- 2022-07-14 KR KR1020220086688A patent/KR20230016148A/ko unknown
- 2022-07-14 CN CN202280050296.0A patent/CN117716238A/zh active Pending
- 2022-07-14 EP EP22842474.3A patent/EP4375670A1/en active Pending
-
2024
- 2024-01-16 US US18/413,322 patent/US20240141036A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
KR20180117066A (ko) * | 2017-04-18 | 2018-10-26 | 주식회사 굳티셀 | Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도 |
KR20210075117A (ko) * | 2018-10-05 | 2021-06-22 | 세인트 안나 킨더크렙스포르슝 | 키메라 항원 수용체(car) 그룹 |
KR20190027808A (ko) * | 2019-03-08 | 2019-03-15 | 주식회사 굳티셀 | 조절자 T 세포에 특이적으로 존재하는 새로운 표면단백질 Lrig-1의 용도 |
KR20200112745A (ko) * | 2019-03-20 | 2020-10-05 | 주식회사 굳티셀 | 뇌신경계 질환의 예방 또는 치료용 조성물 |
KR20210056280A (ko) * | 2019-11-08 | 2021-05-18 | 주식회사 굳티셀 | 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체 |
Also Published As
Publication number | Publication date |
---|---|
US20240141036A1 (en) | 2024-05-02 |
CN117716238A (zh) | 2024-03-15 |
KR20230016148A (ko) | 2023-02-01 |
EP4375670A1 (en) | 2024-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019225777A1 (ko) | 항-ror1 항체 및 그 용도 | |
WO2015133817A1 (ko) | B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도 | |
WO2019225787A1 (ko) | 항-b7-h3 항체 및 그 용도 | |
WO2018194380A2 (ko) | Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도 | |
WO2015058573A1 (zh) | 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途 | |
WO2016137108A1 (en) | Novel antibody binding to tfpi and composition comprising the same | |
WO2014077648A1 (ko) | 인간 및 마우스 l1cam 단백질에 특이적으로 결합하는 항체 및 이의 용도 | |
WO2018030806A1 (ko) | 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물 | |
WO2022039490A1 (en) | Anti-b7-h4/anti-4-1bb bispecific antibodies and use thereof | |
WO2018128454A1 (ko) | 항 α-SYN 항체 및 그 용도 | |
WO2018222019A1 (ko) | 신규한 항-cd40 항체 및 이의 용도 | |
WO2018026248A1 (ko) | 프로그램화된 세포 사멸 단백질(pd-1)에 대한 신규 항체 및 이의 용도 | |
WO2021235696A1 (ko) | Cd22에 특이적인 항체 및 이의 용도 | |
WO2023277361A1 (ko) | 메소텔린 특이적 항체 및 이의 용도 | |
WO2020080853A1 (ko) | Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도 | |
WO2022177394A1 (ko) | Pd-l1 및 cd47에 대한 이중특이적 단일 도메인 항체 및 이의 용도 | |
WO2020101365A1 (ko) | 안정성이 향상된 항 c-met 항체 또는 그의 항원 결합 단편 | |
WO2022103245A1 (ko) | Sars-cov-2에 대한 단일 도메인 항체 및 이의 용도 | |
WO2016199964A1 (ko) | 분리된 비멘틴 유래 펩타이드에 특이적으로 결합하는 항체 또는 상기 펩타이드의 결합 단편 | |
WO2021101346A1 (en) | Anti-ror1/anti-4-1bb bispecific antibodies and uses thereof | |
WO2019045182A1 (ko) | 비멘틴 유래 펩타이드에 특이적으로 결합하는 물질을 포함하는 피부질환 예방 및 치료용 조성물 | |
WO2023287212A1 (ko) | 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체 | |
WO2020022782A1 (ko) | 면역 관련 질환의 예방 또는 치료용 조성물 | |
WO2019216675A1 (ko) | 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체 | |
WO2022145739A1 (en) | Humanized antibody specific for cd22 and chimeric antigen receptor using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22842474 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280050296.0 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022842474 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022842474 Country of ref document: EP Effective date: 20240216 |